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Abstract 
 
The platelet C type lectin-like type II (CLEC-2) transmembrane receptor has been 
shown to interact with its endogenous ligand, podoplanin, on lymphatic 
endothelium and mediate separation from blood vessels. Here, conditional 
deletion of CLEC-2 or a mutation in signalling molecule Syk, specifically in the 
megakaryocyte/platelet lineage, was seen to cause a severe blood-lymphatic 
mixing phenotype. As constitutive loss of CLEC-2 in mice is lethal at birth, 
radiation chimeras have been pivotal to investigating the role of CLEC-2 in platelet 
function. This pilot study was conducted to investigate the role of platelets in the 
recovery from radiation injury. Mice were subjected to irradiation and reconstituted 
with CLEC-2+/+ or CLEC-2-/- foetal liver cells. Immunofluorescence in the intestinal 
mesentery at 9 days showed disrupted vasculature in CLEC-2-/- mice. The only 
visible difference between the two sets of chimeras was blood in the intestine of 
CLEC-2-/- mice at 28 days. Terminal deoxynucleotidyl end labeling (TUNEL) 
showed no difference in the percentage of apoptotic cells in the livers of CLEC-2+/+ 
and CLEC-2-/- mice but an increase in the spleen. These results support the idea 
of a progressive intestinal phenotype and support a role for CLEC-2 and Syk in 
the separation and organization of blood and lymphatic vessels.  
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1.0. Introduction 
 
1.1. Platelet function and signalling 
 
Platelet activation and the formation of platelet aggregates play vital physiological 
roles in maintaining vascular integrity and preventing severe blood loss resulting 
from tissue trauma. However, platelets can also respond to atherosclerotic plaque 
rupture leading to myocardial infarction or stroke[1]. The main platelet activating 
glycoproteins and their intricate signalling pathways have thus become key 
therapeutic targets. Platelet activation in response to soluble platelet ligands such 
as thrombin, ADP or thromboxane A2 occurs through heterotrimeric G proteins 
which orchestrate the activation of several downstream effectors[2]. The major 
platelet collagen receptor, GPVI, activates platelets through an alternative 
mechanism, involving a sequential multi-step pathway in which Src family kinases 
(SFK) phosphorylate the immunoreceptor tyrosine-based activation motif (ITAM) in 
the Fc receptor (Fcr) -chain to which the tyrosine kinase Syk is recruited[3]. A 
similar mechanism is employed by CLEC-2, however, here SFK’s are thought to 
modulate Syk activity which directly mediates phosphorylation of the tyrosine 
residues in the CLEC-2 cytoplasmic tail and hence its own recruitment[4].  In 
contrast, Syk is recruited independently of an ITAM to the platelet integrin αIIbβ3, 
associating with the integrin β3 cytoplasmic tail (Figure 1). Despite these 
differences, each pathway uses a similar, yet distinct series of downstream 
signalling proteins to ultimately activate PLC2 and induce various platelet 
activating effects[5]. 
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1.2. CLEC-2 
 
CLEC-2 is a 30 kDa type II transmembrane protein expressed at high levels on 
platelets and megakaryocytes with low expression on a subpopulation of other 
hematopoietic cells. Initial identification and characterisation of CLEC-2 was 
achieved through the observed potent platelet activation induced by the 
exogenous ligand, the snake venom toxin, rhodocytin[6]. Following this, the 
transmembrane glycoprotein podoplanin was discovered as an endogenous ligand 
for CLEC-2, eliciting powerful platelet activation and secretion in a manner 
reminiscent to rhodocytin. Podoplanin is expressed on type 1 lung alveolar cells, 
lymphatic endothelium, kidney podocytes and tumour cells and remains the only 
known endogenous ligand for CLEC-2 to date[7].  CLEC-2 appears to play a 
fundamental role in thrombus formation, however, given the absence of a ligand 
for CLEC-2 in the blood vasculature, the mechanism behind its role in hemostasis 
and thrombosis remains unknown[8-10].  
As discussed, platelet receptors GPVI and CLEC-2 utilise a similar niche of 
downstream signalling proteins but the initial recruitment of tyrosine kinase Syk 
occurs via two distinct mechanisms. The GPVI receptor recruits Syk via its tandem 
SH2 domains to the phosphorylated tyrosine residues within its two YxxL motifs 
(ITAMs) in the Fc -chain (Figure 1)[2]. In contrast, CLEC-2 has only a single YxxL 
motif in its cytoplasmic tail, known as a hemiITAM, and it is suggested that CLEC-
2 signals through a unique crosslinking mechanism encompassing two 
phosphorylated hemi-ITAMs, bridged by a single Syk molecule (Figure 1)[4, 11].  
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Figure 1. Recruitment of Syk to platelet signalling molecules, GPVI, CLEC-2 and 
integrin αIIbβ3. Tyrosine residues within the Fcr -chain of GPVI and the 
cytoplasmic tail of CLEC-2 become phosphorylated and recruit Syk through 
alternative mechanisms; Two ITAMs in the Fcr -chain bind a single Syk molecule 
whereas Syk crosslinks CLEC-2 through binding to a hemiITAM in each 
cytoplasmic tail. Conversely, the β3 tail of integrin αIIbβ3 interacts with the N-
terminal SH2 domain of Syk independent of an ITAM. Each signalling pathway 
utilises varied downstream signalling molecules to ultimately activate PLC2. 
Modified from Watson et al 2005; 2010[2, 5]. 
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1.3. Development of blood and lymphatic vasculature 
 
The lymphatic system consists of a vast capillary network that functions to drain 
protein-rich interstitial fluid (lymph) from the extracellular spaces within organs and 
return it to the venous circulation.  Other components of the lymphatic system 
include the lymphoid organs; spleen, Peyer’s patches, lymph nodes, tonsils and 
thymus, which have essential roles in the immune response[12].  
It is known that platelets appear in the circulation around embryonic day (E) 8.5, at 
which point the blood vasculature is already established. The lymphatic system 
develops secondary, yet parallel to the blood vasculature, appearing around 
E10.5, where according to Sabin’s widely accepted model[13], endothelial cell 
budding from local veins migrate to form the primary lymph sacs. The lymphatic 
network then spreads through endothelial sprouting to peripheral organs and 
tissues to form local capillary networks[14]. 
Until recently, studying the process of lymphatic development has been hindered 
by the lack of lymphatic specific markers. The transmembrane glycoprotein, 
lymphatic vessel endothelial hyaluronan receptor 1 (Lyve-1), is expressed broadly 
throughout the embryonic vasculature and is thought to represent the earliest sign 
of lymphatic commitment[12, 15]. Subsequent loss of blood vascular markers and 
gain of the transcription factor, prospero related homeobox 1 (Prox-1), around 
E10.5, commits cells to bud from veins and differentiate into lymphatic endothelial 
cells (LECs)[16]. The mature lymphatic vasculature is completely independent of 
the blood vascular system aside from connections at the thoracic and right ducts 
with the subclavian vein, allowing the lymphatic drainage into the blood system 
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while preventing blood reflux into the lymphatic system through specialised 
valves[17]. 
 
1.4. The role of platelets and CLEC-2 in lymphatic development 
 
A number of mouse models have been generated which show defects in the 
separation of blood vasculature from lymphatic vasculature resulting in the 
appearance of blood filled lymphatic vessels in the skin[17]. The mechanisms that 
mediate blood and lymphatic vascular separation during embryonic development 
are poorly understood. Podoplanin on the surface of LEC’s has been found to 
interact with CLEC-2 on platelets to facilitate the separation of blood and lymphatic 
vessels[18]. Podoplanin deficient mice develop a severe blood-lymphatic mixing 
phenotype mid-gestation and die shortly after birth due to an inability to inflate 
their lungs[19, 20]. The appearance of blood-filled lymphatic vessels have also been 
seen in mice deficient in CLEC-2 or its downstream signalling partners, Syk, SLP-
76 and PLC-γ2; notably, this defect does not manifest upon deletion of the GPVI 
FcR-γ chain or integrin αIIbβ3 which also signal through these proteins[9, 21-23]. 
Taken together, the discovery of podoplanin as an endogenous ligand for CLEC-2 
suggests podoplanin on the surface of LEC’s interacts with CLEC-2 on platelets to 
mediate the separation of blood and lymphatic vasculature, involving platelet 
signalling through Syk, SLP-76 and PLC (Finney et al, manuscript submitted for 
publication). 
Recent work looking further into the role of CLEC-2 and Syk in embryonic 
development led to the analysis of mice constitutively deficient in CLEC-2 (CLEC-
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2-/-) and Syk (Syk-/-) and compared these to mice containing a specific deletion of 
CLEC-2 or Syk in the megakaryocyte/platelet lineage. Both constitutive and 
platelet specific CLEC-2-/- and Syk-/- embryos presented with oedema, 
haemorrhaging in the brain and evidence of blood filled lymphatic vessels (Finney 
et al, manuscript in preparation).   
In order to further dissect the specific platelet signalling pathways involved in the 
separation of blood and lymphatic vasculature, a second mouse model was 
generated containing a mutated arginine residue (R41A) in the SH2 domain of 
tyrosine kinase Syk. The R41A mutation specifically prevents Syk interacting with 
the phosphorylated hemiITAM and ITAM receptors, such as CLEC-2 and GPVI, 
leaving the Syk interaction with other platelet receptors, such as integrins, 
unperturbed.  
 
1.5. Radiation chimeras in investigating damage and recovery processes 
 
Constitutive CLEC-2-/- mice are embryonically lethal.  Bone marrow radiation 
chimeras provide a means for producing adult mice with platelets lacking CLEC-
2[10]. In this model, irradiation kills all rapidly proliferating and haematopoietic 
progenitor cells, including those of the platelet lineage and allows effective 
reconstitution of the bone marrow with a donor foetal liver cell line carrying the 
mutation of interest[24].  Irradiation suppresses the host immune system to allow 
the graft time to manifest immunological competence; however, in extreme cases 
the host may mount an overwhelming immune response against the graft resulting 
in rejection and possibly death.  More generally, radiation chimeras manifest with 
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tissue damage, specifically to the lymphatic tissues (e.g. spleen and lymph 
nodes), gastrointestinal tract and the liver, although they recover[25]. 
Previous work in characterising CLEC-2 confirmed the successful application of 
irradiation in providing a selective loss of CLEC-2 in mice reconstituted with 
CLEC-2-/- foetal liver cells[10]. In addition, on-going work looking into the impaired 
recovery of lymphatic vessels when reconstituted with CLEC-2-/- as oppose to 
CLEC-2+/+ foetal liver cells (Barone et at, unpublished observations), prompted the 
need for a pilot study to investigate the basal level of damage incurred by radiation 
and allow direct association of the effects caused by CLEC-2-/- platelets.  
 
1.6. Aims of the study 
 
The initial aim of the study was to genotype the R41A mice to confirm the 
presence of the megakaryocyte specific R41A Syk mutation. Through the use of 
timed matings, embryo dissection and photography, the phenotype of R41A 
embryos during development was to be recorded and comparisons made to the 
existing CLEC-2-/- phenotype.  
To investigate the role of CLEC-2 and Syk in recovery to radiation damage, mice 
were to be subject to radiation and reconstitution with CLEC-2+/+ or CLEC-2-/- 
foetal liver cells and sacrificed at different time points. Mice were phenotypically 
analysed, blood taken for platelet studies and tissues dissected for 
immunohistochemistry, immunofluorescence and TUNEL labelling to investigate 
the damage and recovery processes occurring. 
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2.0. Methods 
 
2.1. Materials 
 
Primary antibodies used in this study were rabbit anti-mouse Prox-1 (Abcam), 
rabbit anti-mouse Prox-1 (Angiobio), hamster anti-mouse podoplanin (Angiobio), 
rat anti-mouse EphrinB4 (Abcam), rabbit anti-mouse SP-C (Seven Hills), rat anti-
mouse Endomucin (Santa Cruz Biotechnology), rat anti-mouse CD-31-FITC (BD 
biosciences), rabbit anti-mouse Lyve-1 (Abcam), rat anti-mouse CD41-FITC (BD 
Biosciences Pharmigen) and rat anti-mouse CLEC-2 was a gift from Caetano Reis 
e Sousa & Diego Mourão-Sá, Cancer research UK, London. Antibodies used for 
secondary detection were biotinylated goat anit-hamster IgG (Angiobio), FITC 
conjugated swine anti-rabbit IgG (Dako Cytomation), Alexa Fluor® 488- or 594 
conjugated goat anti-rat IgG (Invitrogen), Alexa Fluor® 532 conjugated goat anti-
rabbit IgG (Invitrogen). Additional materials used include optimum cutting 
temperature (O.C.T) compound (Cell Path), Dullbeccos 1 X PBS (Gibco), 
VECTASTAIN® Elite® ABC Reagent, DAB substrate chromagen and Vectormount 
mounting medium (Vector laboratories inc), CLEC-2+/+, CLEC-2-/- and common 
primers (Invitrogen),  R41A forward and reverse primers (Ozgene), R41 platelet 
factor 4 (PF4) Cre forward and reverse primers (Invitrogen). RedTaq®ReadyMixTM 
and Water PCR Reagent (Sigma Aldrich). 
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2.2. Genotyping   
 
Mouse ear or tail clippings were digested in lysis buffer (100 mM Tris-HCL, 5 mM 
EDTA, 0.2% SDS, 200 mM NaCl, pH to 8.5) and proteinase K (1 µg/ml) overnight 
at 55°C. Samples were centrifuged at 13,000 g for 10 min to pellet undigested 
debris, isopropanol was added to supernatant and shaken until a DNA aggregate 
was visible which was transferred to approximately 80 µl of Millipore water, 
volume adjusted according to aggregate size. If no DNA aggregate was visible, 
samples were centrifuged at 13,000 g for 20 min to pellet DNA and water added to 
the pellet. Samples were incubated at 55°C until DNA dissolved (approximately 1 
hour) and stored at -20°C until use.  
Mice were genotyped by PCR amplification of mouse genomic DNA. Where 
relevant, the following primers; CLEC-2+/+, CLEC-2-/- and common primers, R41A 
forward and reverse primers and R41 PF4-Cre forward and reverse primers 
(sequences listed in Table 1) were combined in the appropriate volumes with 
RedTaq®ReadyMixTM and Water PCR Reagent on ice to form a mastermix of 
which 19 µl was added to 1 µl of each genomic sample. Mixes containing genomic 
DNA for R41A and CLEC-2 were subject to the following PCR programme; 95°C, 
5 mins, 95°C, 30 sec, 60°C, 30 sec, 72°C, 1 min, repeat steps 2-4 for 35 cycles, 
72°C, 10 mins, 4°C forever. Mixes containing genomic DNA for PF4-Cre 
genotyping were subject to PCR programme, 95°C, 2 mins, 95°C, 30 sec, 56°C, 1 
min, 68°C, 4 min, repeat steps 2-4 for 34 cycles, 72°C, 3 mins, 4°C forever. DNA 
bands were visualized using ethidium bromide on a 1.5% agarose gel. 
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2.3. Animal studies 
 
All animal studies were conducted in accordance with Home Office protocols in 
compliance with project license 30/2721. All animal handling was done by a 
licensed individual. 
 
2.31. Radiation chimera studies 
 
2.311. Preparation of foetal liver cells 
 
Foetal liver cells (previously prepared by Dr Craig Hughes, stored in 90% foetal 
calf serum and 10% dimethyl sulfoxide (DMSO)), derived from CLEC-2+/+ or 
CLEC-2-/- mouse livers at embryonic days 14-16 were removed from liquid 
nitrogen storage, thawed at 37°C and re-suspended in an excess of Dullbeccos 1 
X PBS. Cells were pelleted at 13, 000g for 5 min, supernatant removed and re-
suspended in phosphate buffered saline (PBS) to give approximately 1-2 x 106 
foetal liver cells per mouse.  
 
2.312. Generation of chimeric mice 
 
8 week old C57BL/8 mice (supplied by Harlan, UK) were kept on Baytil for one 
week before receiving two doses of radiation each 500 Rad, 3 h apart. Mice were 
then reconstituted by tail vein intravenous injection of 1-2 x 106 CLEC-2 +/+ or 
CLEC-2-/- foetal liver cells.  
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2.313. Platelet studies 
 
Mice were culled at 1, 9, 21, 28 and 67 days post injection by inducing 
unconsciousness with isofluorane anaesthesia followed by CO2 asphyxiation. The 
intestines of mice at 21 and 28 days were excised and photographed. At 9, 21, 28 
and 67 days blood was drawn from the inferior vena cava into acid citrate dextrose 
(ACD) (1/9 vol), transferred into modified HEPES Tyrode buffer (134 mM NaCl, 
2.9 mM KCl, 12 mM NaHCO3, 0.34 mM NaH2PO4, 1 mM MgCl2, 5.5 mM glucose, 
1 mM MgCl2, 20 mM HEPES [pH 7.3]) and taken for whole blood counts (ABX 
diagnostics). On days 9, 21 and 28, platelet rich plasma (PRP) was prepared by 
centrifugation (2 x 5 min spins at 2000 rpm) and diluted in HEPES Tyrode buffer to 
approximately 2 x 107 platelets/ml for flow cytometric analysis (FACS) (BD 
Biosciences) with antibodies against CLEC-2, CD41 and the respective IgG 
controls. Forward/side scatter gates were set to exclude non-viable cells.  
 
2.314. Tissue harvesting and fixation 
 
At 24 hr, the intestinal mesentery, intestine, liver and spleen were dissected, snap 
frozen in liquid nitrogen and stored at -80°C for cryosectioning. At 9, 21 and 28 
days, the inguinal lymph nodes and intestinal mesentery were dissected and fixed 
(as described in 2.41) for whole mount immunostaining. Intestine, liver, spleen and 
mesenteric lymph nodes were dissected and embedded in O.C.T, snap frozen in 
liquid nitrogen and stored at -80°C for cryosectioning. 
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2.32. Harvesting and fixing CLEC-2 and R41A embryos 
 
Pregnant females were culled at E 14.5 or E 16.5 by schedule 1 procedures, 
embryos removed into cold PBS and tail clippings taken for genotyping (see 
methods, 2.2). Embryos were gently removed from their membranes and 
photographed followed by fixing in 4% paraformaldehyde/PBS at 4°C for 90 min. 
Embryos were then cryoprotected in 20% sucrose/PBS overnight at 4°C. Embryos 
were snap frozen in liquid nitrogen and stored at -80ºC prior to cryosectioning into 
8 µm sections.  
 
2.4. Immunofluorescence staining 
 
2.41. Whole mount 
 
For whole mount immunostaining, tissues were directly fixed in acetone for 15 
min; sections of intestinal mesentery at 21 and 28 days were spread over circular 
glass coverslips prior to fixing. Tissues were washed in PBS and incubated in 50 
mM ammonium chloride for 30 min at room temperature (RT) with gentle shaking. 
Tissues were washed in PBS, 0.3% Triton X-100 (PBS-TX), blocked in 3% 
BSA/PBS-TX for 1 hour at RT followed by overnight incubation with gentle shaking 
at 4°C in primary antibodies to Lyve-1 and Endomucin (diluted in 3% BSA/PBS-
TX).  Tissues were washed extensively in PBS-TX and incubated overnight at 4°C 
with gentle shaking in secondary antibodies, IgG-FITC and Alexa Fluor®594, 
diluted in PBS-TX. Following extensive washing in PBS-TX, tissues were mounted 
onto a Colorfrost® Plus, charged microscope slide with a glass coverslip.  Images 
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were obtained using a Leica SP2 confocal microscope using a 10X objective (0.3 
Ph1) equipped with 488 and 543 lasers to excite FITC and Alexa Fluor®594, 
respectively. Images were processed using Adobe Photoshop 8.0. 
 
2.42. Immunofluorescence of cryosections 
 
For optimisation of immunostaining for cryosections, slides were removed from -
80ºC and left at room temperature (RT) for 30 min or until dry. Where stated, 
sections were fixed in pre-cooled acetone at -20°C for 20 min. Following washing 
in PBS, 0.1% Tween (PBST), where stated, slides were quenched with 50 mM 
ammonium chloride and subsequently washed in PBST. Slides were blocked with 
20% BSA/PBST or 10% goat serum in PBST, as stated in figure legends. Slides 
were incubated with primary antibody/antibodies, diluted in the relevant blocking 
solution, for 1 hour at RT (in dark where CD31-FITC applied) or overnight at 4°C 
followed by extensive washing in PBST. Slides were then incubated with 
secondary antibody/antibodies, diluted in the relevant blocking solution for 1 hour 
at RT in the dark followed by extensive washing in PBST. After 5 min incubation in 
the dark with To-pro-3-Iodide, diluted 1:2000, slides were washed extensively in 
PBST, left to dry at RT, mounted with Vectashield and stored at 4°C prior to 
confocal microscopy. Images were obtained using a Leica SP2 confocal 
microscope using a 10X (0.3 Ph1) or 40X oil objective (1.3 oil) equipped with 488 
and 633 lasers to excite FITC and To-pro-3-iodide, respectively. Images were 
processed using Adobe Photoshop 8.0. 
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2.43. Immunohistochemistry  
 
For immunostaining of paraffin sections, slides were de-waxed and dehydrated by 
immersion in xylene substitute (5 min), 100% ethanol (3 min), 90% ethanol (30 
sec), 75% ethanol (30 sec), 50% (30 sec), 30% (30 sec), H20 (3-5 min). Slides 
were then subject to the following antigen retrieval steps; Prox-1 treated slides 
were boiled in citrate buffer (2.94g Tris sodium citrate/1L water, 0.5% Tween, pH 
to 6) for 40 min. Podoplanin treated slides were microwaved in citric acid buffer 
(2.1g citric acid monohydrate/1L water, pH to 6) on full power for 3-4 min followed 
by 15 min on medium power. Slides were cooled to RT, washed in PBST and 
subject to an endogenous peroxidase block of 3% H202 for 10 min at RT followed 
by further washing in PBST. Slides were blocked with 3% BSA/PBST for 1 hour at 
RT and then incubated overnight at 4°C with primary antibody, diluted in blocking 
solution. Slides were washed extensively in PBST before secondary antibody 
incubation, diluted in blocking solution, for 30 min at RT. Following extensive 
washing in PBST slides were incubated in VECTASTAIN® Elite® ABC Reagent for 
30 min at RT followed by further washing in PBST before visualization with DAB 
substrate chromagen solution. Slides were counterstained in Harris’ 
Haematotoxilin, dehydrated in 75% ethanol (3 min), 90% ethanol (3 min), 100% 
ethanol (3 min), xyelene substitute (1-5 min) and then overnight in xyelene 
substitute. Slides were dried off and mounted using VectorMount mounting 
medium. Images were obtained using a Zeiss Axiovert Zoom brightfield 
microscope using a 10X (0.3 Ph1) or 40X oil objective (1.3 oil). Images were 
processed using Adobe Photoshop 8.0. 
15 
 
2.44. TUNEL assay 
 
TUNEL assays were performed according to the manufacturer’s instructions on 
CLEC-2+/+ E14.5 embryo cryostat sections and spleen, liver, intestine and 
mesenteric lymph node cryostat sections from CLEC-2+/+ and CLEC-2-/- radiation 
chimeras. Slides were counterstained with To-pro-3-Iodide for confocal 
microscopy or with DAPI for widefield epi-fluorescent microscopy, diluted 1:2000 
or 1:1000, respectively in PBS and incubated for 10 min at RT. Slides were 
washed extensively in PBS before mounting with Vectashield and stored at 4°C. 
For quantitative assaying, sections of spleen and livers from radiation chimeras 
were cut 20 μm apart, images taken on the widefield epiflourescent microscope 
and the percentage of apoptotic cells per DAPI stained nuclei calculated. Images 
were obtained using a Zeiss Axiovert Zoom invert epi-fluorescence microscope 
using a 40X oil objective (1.3 oil). Images were processed using Adobe Photoshop 
8.0. 
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3.0. Results 
 
3.1. Genotyping and phenotyping R41A mice 
 
The generation of a megakaryocyte/platelet specific knock in mutation, R41A, 
within signalling molecule Syk was achieved through implementation of a loxP-Cre 
strategy utilising the PF4 promoter to direct expression of the mutated allele in the 
megakaryocyte lineage.  Mice homozygous for the floxed allele, R41Afl/fl (Figure 
2A and B, band 1) are crossed with mice expressing Cre recombinase from a PF4 
promoter (Figure 2B, bands 3,4 and 5).  Cre recombinase allows excision of the 
insert containing the wild-type R41 site flanked by the two lox P sites (Figure 2A) 
to allow expression of the Syk gene containing the R41A mutation within the 
megakaryocyte lineage (Ozgene). R41A mice were genotyped to accurately 
confirm the absence or presence of mutated (floxed) alleles in conjunction with the 
PF4-Cre expressing insert (Figure 2B). 
The primary aim in researching the R41Afl/fl PF4-Cre mice was to characterise 
their developmental phenotype, in particular, observing any similarities and 
differences to the megakaryocyte/platelet specific CLEC-2-/- mice (CLEC-2fl/fl PF4-
Cre).  Figure 3 highlights the severity of the developmental defects observed at 
E14.5 in R41Afl/fl PF4-Cre embryos and the striking similarity to those seen at 
E14.5 in CLEC-2fl/fl PF4-Cre embryos. Both R41Afl/fl PF4-Cre and CLEC-2fl/fl PF4-
Cre embryos presented with severe oedema, haemorrhaging in the brain and 
blood filled lymphatic vessels (Figure 3). 
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3.2. Optimising protocols for immunostaining 
 
3.21. Immunohistochemistry of paraffin sections 
 
In order to practice the immunostaining technique, a protocol for podoplanin 
immunohistochemistry which had previously been optimised in the lab was used to 
stain both CLEC-2+/+ and CLEC-2-/- mouse adult lung paraffin sections. This 
demonstrated that CLEC-2+/+ mouse lungs appeared much more developed and 
equipped for gas exchange as oppose to CLEC-2-/- mouse sections which 
appeared under-developed, likely contributing to the embryonic lethality of these 
mice (Figure 4A). Despite this observation, both CLEC-2+/+ and CLEC-2-/- mice 
display the same developmental progressive expression of podoplanin in larger 
airways as they become adapted for gas exchange (Figure 4A). Additionally, only 
in CLEC-2-/- mice was there evidence for blood cells residing in lymphatic vessels, 
supporting the blood, lymphatic mixing phenotype and defective lymphatic 
vasculature commonly associated with this mutation (Figure 4B).  
A key interest associated with this project, to be discussed later in the text, was 
the effect of CLEC-2-/- platelets on lymphatic vessel recovery in response to 
damage.  It was therefore desirable to develop an efficient immunohistochemistry 
protocol for the LEC marker Prox-1, given the incomplete lymphatic specificity of 
the currently used LEC marker, Lyve-1[26]. However, the Prox-1 antibody (Abcam) 
proved to be highly temperamental and a variety of adaptations from the 
podoplanin immunohistochemistry protocol were trialled with only a few successful 
staining results (Figure 5), which occurred inconsistently.  The main obstacle here 
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was considered to be the antigen retrieval steps where sections had to be subject 
to significant and extended boiling times. 
 
3.22. Immunofluorescence of frozen sections  
 
In light of these results it was decided to use frozen sections where proteins 
remain in their correct configuration for antigen binding. Since 
immunofluorescence of frozen sections was a new technique to the lab, a variety 
of protocols were attempted using a number of different antibodies of interest. No 
specific staining was observed for podoplanin, Prox-1 (Angiobio - chosen for 
increased suitability for immunofluorescence) or ephrin B4, a receptor tyrosine 
kinase with key roles in vascular development[27]. Consequently an antibody to 
pro-SPC, a transmembrane protein found in type I alveolar cells in the lung[28], 
known in the lab to work effectively for immunofluorescence staining of mouse 
adult lung sections, was tested to ensure the correct technique was being applied. 
Staining for pro-SPC was successful (Figure 6) and so at this point it was decided 
to interact with Professor Chris Buckley's lab (School of immunity and infection, 
University of Birmingham), who work effectively with immunofluorescence of 
frozen sections in order to develop a robust protocol for successful staining with 
the antibodies of interest.  
Following protocol development, specific staining for CD31 was observed on both 
embryonic mouse cryosections and spleen and liver cryosections from radiation 
chimeras (Figure 7).  However, immunofluorescence staining for podoplanin, Prox-
1 and Lyve-1 required further enhancement to improve specificity. The inability at 
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this stage to reliably and reproducibly stain for a variety of antibodies of interest 
led to research into alternative assays that could be employed to investigate the 
extent of damage and recovery processes occurring in tissues of radiation 
chimeras. 
 
3.3. Investigating damage and recovery processes in radiation chimeras 
 
A pilot study was conducted to investigate the damage caused by radiation in 
different tissues to enable comparisons of recovery processes in mice 
reconstituted with CLEC-2+/+ or CLEC-2-/- foetal liver cells (Figure 8). 
 
3.31. Platelet studies 
 
Analysis of platelets at 9, 21, 28 and 67 days post radiation and reconstitution, 
show as expected, both CLEC-2+/+ and CLEC-2-/- mice were initially severely 
thrombocytopenic (64-144 x103/μl)  and recovered towards having platelet counts 
within a normal range (900-1600 x103/μl) by 28 days (Figure 9)[29]. 
Correspondingly, mean platelet volume (MPV) was highly increased at day 9 
following radiation treatment (12-17 μm3) highlighting the presence of immature 
platelets[30]. MPV for both CLEC-2+/+ and CLEC-2-/- reconstituted mice returned to 
within the normal range (4-6μm3) by 21 days outlining no significant differences 
between the two groups in platelet counts and MPV over time (Figure 9)[29]. 
Fluorescence activated cell sorting (FACS) analysis confirmed the presence of 
platelet populations in both CLEC-2+/+ and CLEC-2-/- reconstituted mice, indicated 
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by the shift in CD41 (αIIb) staining, a major platelet glycoprotein, as compared to 
the IgG control (Figure 10). Conversely, CLEC-2 staining of platelets showed only 
mice reconstituted with CLEC-2+/+ foetal liver cells were positive for CLEC-2 at 21 
and 28 days, confirming the loss of CLEC-2 from the megakaryocyte lineage in 
mice reconstituted with CLEC-2-/- foetal liver cells (Figure 10). 
 
3.32. Phenotyping radiation chimeras 
 
Prior to and during dissection, all mice were visually analysed and any differences 
between CLEC-2+/+ and CLEC-2-/- chimeras were photographed. No visible 
adverse effects to radiation were observed prior to 28 days post reconstitution. At 
28 days, the accumulation of blood in the intestine could begin to be seen in mice 
reconstituted with CLEC-2-/- foetal liver cells which was not visible in CLEC-2+/+ 
chimeras (Figure 11A). It has previously been noted at 8 weeks that 
megakaryocyte/platelet specific CLEC-2-/- mice show considerable accumulation 
of blood in the intestine (Figure 11B) (Finney et al, manuscript in preparation).  
Following on from the difficulties experienced in optimising immunofluorescence of 
frozen sections, whole mount staining was trialled on the inguinal lymph nodes 
and intestinal mesentery. Blood and lymphatic vasculature were visible at 9 days 
post radiation in the intestinal mesentery and appeared organised in CLEC-2+/+ 
compared to CLEC-2-/- chimeras where vasculature seemed highly disrupted and 
damaged indicating a severe impairment of functionality (Figure 12).  
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High levels of background fluorescence in the inguinal lymph nodes and intestinal 
mesenteric sections at 21 and 28 days prevented images being taken for analysis 
despite the presence of visible, specific staining. 
 
3.33. TUNEL labelling of apoptotic cells 
 
In light of the difficulties experienced with immunofluorescence of frozen sections, 
alternative assays were considered to investigate the extent of damage over time 
in tissues most susceptible to radiation damage. The TUNEL assay was employed 
for specific labelling and detection of cells undergoing apoptosis (Figure 13). 
TUNEL assays were trialled on spleen and liver cryosections from radiation 
chimeras 9 days post radiation and on CLEC-2+/+ E14.5 embryo cryosections, 
known to encompass detectable levels of apoptotic cells due to the essential role 
of apoptosis in embryonic development[31]. The assay was performed according to 
the manufacturer’s instructions and rigorous analysis ensured the correct 
alignment of rhodamine staining with To-pro-3-iodide stained nuclei (Figure 14). 
Positive TUNEL labelling was also visible in the intestine and mesenteric lymph 
nodes of radiation chimeras (data not shown).  
To allow for quantification of the levels of apoptosis in the spleen and livers of 
radiation chimeras at various time-points following radiation, TUNEL labelling was 
performed on cryosections 20 μm apart and the percentage of apoptotic nuclei 
relative to DAPI stained nuclei were calculated. No substantial difference in the 
percentage of apoptotic cells between CLEC-2+/+ and CLEC-2-/- chimeras were 
observed in liver cryosections. Additionally, although the number of apoptotic cells 
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were above the negligible number expected in the liver of a healthy animal, larger 
scale quantification is require to add significance to this observation[32]. In the 
spleen, heightened levels of apoptosis were seen in both CLEC-2+/+ and even 
more so in CLEC-2-/- chimeras compared to levels (<2%) that would normally be 
expected (Figure 15)[33]. However, as this was a pilot study only two mice were 
available to be sacrificed at each time point, future studies should aim to increase 
this number along with the number of cryosections analysed per tissue and 
images per cryosection. 
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4.0 Discussion 
 
4.1. R41Afl/flPF4-Cre embryos phenocopy CLEC-2fl/flPF4-Cre embryos 
 
The mechanisms that co-ordinate the intricate separation of blood and lymphatic 
vasculature remain unknown. Mice deficient in the platelet receptor CLEC-2, 
experience defects in lymphatic development as early as E12.5. However, 
whereas constitutive CLEC-2-/- mice are embryonically lethal, where CLEC-2 is 
specifically deleted from the megakaryocyte lineage, using the PF4-Cre strategy 
(CLEC-2fl/fl PF4-Cre), mice are viable and thrive after birth. As discussed, 
podoplanin deficiency results in a similar phenotype with blood/lymphatic 
misconnections. Since podoplanin on the surface of LEC’s has been shown to 
induce potent platelet aggregation, it is speculated that CLEC-2 on platelets is 
directly involved in mediating the separation of blood and lymphatic vasculature[20].  
R41Afl/fl PF4-Cre mice were generated to gain further insight into the role of 
CLEC-2 and signalling molecule Syk in blood and lymphatic separation through 
development. The R41A mutation specifically blocks Syk interacting with 
phosphorylated hemiITAM or ITAM receptors, hence ablating signalling[2].  
Receptors such as integrins interact with Syk through alternative mechanisms and 
are able to signal through Syk and function as normal[5]. Like CLEC-2fl/fl PF4-Cre 
mice the R41Afl/fl PF4-Cre mice live to birth and future studies will aim to establish 
the mechanism behind this phenomenon which is likely to result from the varied 
activity of the PF4 promoter during development (Finney et al, manuscript 
submitted for publication).  
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Initial work in this area involved characterising the phenotype of R41Afl/fl PF4-Cre 
mice which appeared remarkably similar to that of the constitutive CLEC-2-/-  and 
CLEC-2fl/fl PF4-Cre mice at E14.5 where severe oedema, haemorrhaging in the 
brain and blood filled lymphatic vessels were visible (Figure 3). The blood filled 
lymphatic phenotype is common in mice with CLEC-2 signalling defects and is 
thought to result from the improper separation of blood and lymphatic vessels 
during development;  the oedema observed is therefore a likely side-effect of the 
disrupted lymphatic vasculature, unable to efficiently conduct its drainage 
function[9]. Studies in PLC2 null embryos at E13.5, displaying a similar phenotype 
to CLEC-2-/- embryos, reveal the aberrant separation of lymph sacs from the 
cardinal vein thus permitting blood flow into the lymphatic system[23]. Further work 
into locating and characterising the points of misconnection between blood and 
lymphatic vasculature is key towards determining the cause behind the blood filled 
lymphatic phenotype. 
The development of subcutaneous haemorrhaging in the brains of R41Afl/fl PF4-
Cre and CLEC-2fl/fl PF4-Cre embryos are not likely to derive from lymphatic 
dysfunction since the brain is absent of lymphatic vessels. Podoplanin expressing 
epithelial cells have been observed at the choroid plexus of the brain at sites 
which appear to localise with sites of bleeding[34]. Subcutaneous haemorrhaging 
has also been observed in both Syk and SLP-76 deficient embryos[21, 22, 35]. It is 
proposed that podoplanin expressing epithelial cells of the choroid plexus interact 
with circulating platelets to influence to formation of the blood-cerebrospinal fluid 
barrier in the brain through platelet signalling involving CLEC-2 and Syk (Finney et 
al, manuscript submitted for publication). 
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It is of interest to quantify the levels of CLEC-2 on the platelet surface through the 
course of development and through adulthood when it would be expected that the 
requirement of CLEC-2 in the separation of blood from lymphatic vessels would be 
diminished. Additionally, the wide tissue distribution of podoplanin implies the 
CLEC-2-podoplanin partnership may occupy additional, so far undiscovered 
roles[18].  
  
4.2. Obstacles faced in optimising immunofluorescence of frozen sections 
 
In preparation for investigating the damage and recovery processes in tissues of 
radiation chimeras, immunostaining protocols for a variety of antibodies of interest, 
for example, against antigens of the blood and lymphatic vasculature, were to be 
optimised. 
Initial practicing of the immunohistochemistry technique employed a well-
established protocol for podoplanin staining, leading to some interesting 
observations. The airways of the CLEC-2+/+ lungs appeared well developed 
compared to those of constitutive CLEC-2-/- which were visibly under developed 
and appeared insufficient to allow viable gas exchange. Despite this lethal 
phenotype, the airways of CLEC-2-/- mice displayed the same progressive 
expression of podoplanin on type II alveolar cells as seen for CLEC-2+/+ mice 
which is indicative of airways becoming viable for gas exchange. Recent work 
showed constitutive CLEC-2-/- mice presenting at birth with fluid accumulation in 
the lungs, severely reduced airspaces and abnormal lymphatic vascular patterning 
resulting in death shortly after birth (Finney et al, manuscript in preparation). 
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Similar pathology is seen in podoplanin deficient mice which are unable to inflate 
airspaces in the lungs after birth resulting in lethality[36]. Together these 
observations indicate the proper functioning of both podoplanin and CLEC-2 are 
required for viable lung development. During development, branching and 
morphogenesis are influenced by the secretion of fluid into the lumen of the lung 
from the airway epithelium[37]. The integrity of lymphatic vasculature in the lung is 
critical for the clearance of this fluid and likely underlies the inability of CLEC-2-/- 
and podoplanin deficient mice to inflate their lungs. This phenotype is not 
observed in megakaryocyte/platelet specific CLEC-2fl/fl PF4-Cre mice suggesting 
platelets only partly contribute to the defective lung development; alternatively, 
CLEC-2 on another cell types may be responsible for the observed lung 
phenotype (Finney et al, manuscript submitted for publication). Additionally, 
podoplanin stained blood filled LEC’s were observed by neighbouring blood 
vessels which were not seen in CLEC-2+/+ lung tissue, linking the role of CLEC-2 
in blood and lymphatic vessel separation and the development of lethal lung 
pathology. 
The difficulty experienced in optimising a protocol for Prox-1 staining in paraffin 
sections and the subsequent move to frozen sections brought new challenges as 
immunofluorescence of frozen sections was an unfamiliar technique to the lab. 
Individual antibodies require independent optimisation which can be timely and it 
is possible here that the desired antibodies used were not sufficiently suited for 
the immunofluorescence technique. Future work should involve further 
enhancement of blocking techniques to reduce background and employing signal 
amplification strategies to allow increased visibility of specific staining. 
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4.3. Investigating damage and recovery processes in radiation chimeras 
 
Radiation is used widely in cancer treatment and as such the possible side effects 
and most vunerable tissues in man are well characterised to be the skin, gut, 
lymphoid organs and the liver[25]. The damage caused by radiation in the 
generation of chimeric mice is much less well documented and has generally been 
extrapolated from observations in humans. In most instances this is sufficient 
knowledge for the purpose of the study. However, recent studies comparing the 
recovery of lymphatic vessels post radiation between mice reconstituted with 
CLEC-2+/+ or CLEC-2-/- platelets, outlined the need to establish the basal level of 
damage caused by radiation in chimeric mice (Barone, F et al, unpublished 
observations). This would allow for the direct association of the observed defects 
resulting from reconstitution with CLEC-2-/- platelets. In this short project a pilot 
study was conducted to begin to address this question. 
 
4.31. No difference observed in platelet count recovery between CLEC-2+/+ 
and CLEC-2-/- chimeras 
 
As expected, platelet studies showed all chimeric mice were thrombocytopenic at 
9 days post radiation and reconstitution confirming successful depletion of the 
bone marrow, lagging to replenish circulating platelets at a time point when the 
majority will have exceeded their life span[1]. Platelets present at 9 days had mean 
platelet volumes well above the normal range; these immature platelets are 
clinically symbolic post radiation treatment as the bone marrow is overwhelmed in 
its capacity to reconstitute the circulating haematopoietic niche[30]. Looking into the 
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activating capability of this initial platelet niche in response to different platelet 
agonists could have provided insight into the extent to which recovery processes 
are deferred. Both platelet count and mean platelet volume recover to the same 
degree in both CLEC-2+/+ and CLEC-2-/- reconstituted mice as expected since 
CLEC-2 has no known role in platelet production and maturation. The absence of 
CLEC-2 on the platelets of mice reconstituted with CLEC-2-/- platelets was 
confirmed by FACS analysis. 
 
4.32. CLEC-2-/- chimeras show signs of a progressive intestinal phenotype 
 
It has previously been observed that irradiated mice suffer from substantial micro 
vascular endothelial cell death in the small intestine and hence, irradiation 
stimulates vascular repair in chimeras alongside replacing the hematopoietic cell 
niche[38]. Here, no significant adverse effects were observed prior to 28 days post 
radiation at which point the intestines of chimeric mice appeared notably more 
bloody in CLEC-2-/- chimeras. This supports the accumulation of blood in the 
intestine as being a progressive phenotype which becomes increasingly severe by 
8 weeks in megakaryocyte/platelet specific CLEC-2fl/fl PF4-Cre mice (Finney et al, 
manuscript submitted for publication). Connections between blood and lymphatic 
vessels were observed in the intestines of PLC2 radiation chimeras which 
presented with blood and chyle ascites in the intestine. Interestingly, the observed 
blood-lymph shunts could be repaired following treatment with wild-type bone 
marrow cells, confirming the specific role of bone marrow derived cells in the 
vascular separation process[23].  Similarly, the intestinal phenotype observed in 
CLEC-2-/- chimeras was not seen in CLEC-2+/+ chimeras suggesting the impaired 
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recovery to radiation damage results specifically from reconstitution with CLEC-2-/- 
foetal liver cells.  
Interestingly, as early as 9 days post radiation, CLEC-2-/- chimeras appear to have 
more disrupted blood and lymphatic vasculature in the intestinal mesentery, 
visualised by whole mount staining. This mimics the loss of normal blood vessel 
architecture in the intestines of SLP-76 deficient radiation chimeras which was 
found to derive from blood/lymphatic misconnections[39]. In contrast, vasculature in 
CLEC-2+/+ chimeras appeared organised and undamaged, indicating successful 
repair from radiation treatment. This suggests that the cause behind the intestinal 
phenotype discussed begins much earlier than visible. It can be speculated that 
CLEC-2-/- platelets are unable to repair the damage sustained by the vasculature 
from radiation treatment compared to CLEC-2+/+ platelets which have the capacity 
to respond quickly to damage and initiate repair processes. It is however 
surprising that given the suggested incapability of CLEC-2-/- chimeras to respond 
to damage, that these mice do not show any additional obvious pathological side 
effects compared to CLEC-2+/+ chimeras.  
Future studies should look at later time points to investigate the intestinal 
phenotype further since it has been observed that damaging effects caused by 
radiation in CLEC-2-/- chimeras often become lethal by 12 weeks in contrast to 
CLEC-2+/+ chimeras which commonly recover well (Finney et al, manuscript in 
preparation). Additionally, earlier time points are to be studied in 
megakaryocyte/platelet specific CLEC-2fl/fl PF4-Cre mice to enable further 
characterisation of when the phenotype manifests and how quickly it progresses. 
 
30 
 
4.33. Radiation induces elevated levels of apoptosis in liver and spleen 
 
TUNEL assays were performed as a means of comparing the level of damage 
sustained by mice reconstituted with CLEC-2+/+ or CLEC-2-/- platelets.  TUNEL 
labelling is a widely used, robust assay to accurately label apoptotic cells, 
distinguishing them from the abundance of necrotic cells likely to be present in this 
scenario. Quantitative analysis of apoptosis in liver and spleen cryosections 
involved switching from confocal microscopy to widefield epiflouresent microscopy 
to allow quicker, more accurate analysis.  
Although the levels of apoptosis in the liver appeared to increase above the 
negligible levels that would normally be expected[32], no substantial difference was 
observed. Apoptotic cells in the liver were largely individual and spread throughout 
the tissue, as represented in Figure 15Bii, indicating this tissue did not suffer 
extensive damage in response to radiation in either CLEC-2+/+ or CLEC-2-/- 
chimeras.  
It is stated in the literature that <2% of cells in the spleen undergo apoptosis under 
normal conditions[33]. With this in mind the data produced suggest a vast increase 
in apoptosis to what would normally be expected was observed in response to 
radiation damage in CLEC-2+/+ and CLEC-2-/- chimeras. This is not surprising 
since the spleen is a hematopoietic organ holding a large number of 
radiosensitive, highly proliferating cells[40]. The increased levels of apoptosis 
observed in CLEC-2-/- chimeras potentially indicate a lag in recovery and sustained 
damage, however, since a decrease in the level of apoptosis is observed in both 
sets of chimeras at 28 days it is likely this difference not significant.  
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In order clarify these observations, future studies should include more early and 
extended time points as well as increasing the number of mice sacrificed to 
accurately monitor the change in apoptosis levels over time. It would also be 
preferable to increase the number of 20 μm separated cryosections and images 
taken per section to allow a more accurate representation of the level of apoptosis 
occurring in the tissue. 
Crucially, quantitating apoptosis levels in the intestine, a tissue known to be highly 
radiosensitive during the early stages post radiation, could provide valuable 
information in relation the suspected progressive accumulation of blood observed 
in CLEC-2-/- chimeras.  
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5.0. Conclusion 
 
The severe blood lymphatic mixing phenotype observed in both constitutive 
CLEC-2-/- and megakaryocyte/platelet specific CLEC-2fl/fl PF4-Cre and R41Afl/fl 
PF4-Cre embryos provides profound support for the role of platelet receptor 
CLEC-2 and signalling molecule Syk in the separation of blood and lymphatic 
vasculature. CLEC-2-/- radiation chimeras showed signs of a progressive intestinal 
phenotype by 4 weeks thought to derive from the impaired recovery of blood and 
lymphatic vasculature by reconstituted CLEC-2-/- foetal liver cells following 
radiation treatment.  The role of platelets in the development of this phenotype is 
supported by the severe accumulation of blood in the intestine of 
megakaryocyte/platelet specific CLEC-2fl/fl PF4-Cre mice by 8 weeks along with 
previous reports of disrupted vasculature and blood filled intestines of SLP-76 and 
Syk deficient radiation chimeras. Although heightened levels of apoptosis were 
observed in the spleens of radiation chimeras, a highly haematopoetic organ, 
more work is required to determine the role of CLEC-2 and Syk in the recovery 
from radiation damage. 
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6.0. Future directions 
 
In addition to those already listed throughout this report, there are a number of 
aspects to radiation damage and recovery responses that would be interesting to 
study in future work.  
Whole mount triple labelling for platelets (CD41), blood vessels (endomucin) and 
lymphatic vessels (Lyve-1) in the intestinal mesenteric tissue of radiation chimeras 
could provide an interesting viewpoint in visualising the integrity of the vasculature 
in CLEC-2+/+ or CLEC-2-/- chimeras. 
Quantifying the level of necrosis in different tissues would be of interest 
particularly at early time points when tissues such as the liver, spleen and intestine 
are likely to have sustained a high degree of damage. Assays are now available to 
study the number of normal, apoptotic and necrotic cells in concert (PromoKine). 
A major obstacle in bone marrow transplantation comes with the phenomenon of 
‘graft versus host disease’ (GVHD) where the host mounts a lethal immune 
response against the graft (donor cell line) leading to the development of severe 
secondary diseases (diarrhoea, skin changes, liver abnormalities etc) or even 
death. Monitoring the levels of T cell cytokines that promote GVHD progression 
(IL-2, IFN-γ); or measuring markers of inflammation, such as macrophages and 
inflammatory cytokines (e.g. TNF-α, IL-1), would help establish the extent of this 
reaction in different tissues[41].  
Alternative pools of cytokines (e.g. colony stimulating factors) occupy essential 
functions in promoting proliferation of the surviving endogenous haematopoietic 
stem cells to direct their differentiation and functional maturity. Localising and 
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quantifying the abundance of these cytokines in different tissues may help assess 
the tissues capacity for recovery. For example, the spleen has been shown to 
become enriched with CD4+ or natural killer cells which secrete cytokines to 
promote or inhibit haematopoiesis, respectively, in response to radiation[40]. 
Conducting this analysis alongside staining for proliferation markers such as ki67 
would further investigate the regenerative capability of different tissues[42]. 
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7.0. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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Figure 2. Genetic strategy and genotyping of R41A mice. (A) The R41+/+ allele 
encompasses the Syk gene containing the R41 site downstream of an ATG start 
codon. The floxed (fl) allele, R41Afl/fl, contains an insert (white box) including the 
R41+/+ DNA flanked by two lox P sites upstream of second ATG start site and the 
R41A mutated codon.  Amplification occurs preferentially from a second reverse 
primer site to give a 296 base pair (bp) fragment (plus a theoretical but unlikely 
5015 bp fragment from primer rev’). When crossed with a PF4-Cre positive 
mouse, cre recombinase allows excision of the insert flanked by the two lox P 
sites to give the R41Afl/flPF4-Cre allele, specific to the megakaryocyte lineage 
(cannot be genotyped). Diagrams are not to scale. (B) R41A PCR; forward and 
reverse primers allow the amplification of a 229bp fragment from the R41+/+ allele, 
and a 296bp fragment from the R41Afl/fl allele. PF4-Cre PCR; forward and reverse 
primers amplify a 400bp fragment confirming the presence of the cre recombinase 
cDNA insert. Molecular weight markers (bp) shown to the left. See Table 1 for 
primer sequences. 
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Figure 3. Phenotyping R41Afl/flPF4-Cre and CLEC-2fl/flPF4-Cre embryos at E14.5. 
Megakaryocyte/platelet specific R41Afl/flPF4-Cre embryos exhibit a similar 
phenotype to CLEC-2fl/flPF4-Cre embryos with severe oedema (stars), 
haemorrhaging in the brain (arrow heads) and bloody filled lymphatic spots 
(arrows).  Mice homozygous for the flox allele (R41Afl/fl and CLEC-2fl/fl) do not 
exhibit this phenotype in the absence of PF4-Cre. (CLEC-2 images taken by Dr 
Brenda Finney). 
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Figure 4. Immunostaining for podoplanin in adult lung paraffin sections. A and B 
show positive brown staining for podoplanin in type II alveolar cells (A) and LEC’s 
(B). (A) Airways in CLEC-2+/+ lung sections are well developed in contrast to 
CLEC-2-/- mice (10 X); progressive expression of podoplanin is observed in larger 
airways (40 X). (B) Podoplanin stained blood filled LEC’s (arrows) around blood 
vessels (star) in CLEC-2-/- mice. All sections counterstained with Harris 
haematoxilin (blue). Scale bars represent 20 μm. 
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Figure 5. Prox-1 immunostaining of LEC’s in CLEC-2+/+ lung paraffin sections at 
E16.5. Prox-1 stained nuclei (arrows) line LEC’s in the lung. No staining was 
visible when using IgG as a negative control. All sections were counterstained with 
Harris haematoxilin (blue). Scale bars represent 20 μm. 
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Figure 6. Immunofluorescence of mouse adult lung sections with pro-SP-C. Type I 
alveolar cells stained for pro-SP-C (FITC-green), no staining observed for the IgG 
negative control. Sections were quenched with ammonium chloride and blocked 
with 20% BSA/PBST. Nuclei counterstained with To-pro-3-iodide (blue). Visualised 
by confocal microscopy. 
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Figure 7. Immunofluorescence of frozen sections with CD31-FITC.  Embryonic 
CLEC-2+/+ mouse sections (E14.5), spleen and livers of CLEC-2+/+ radiation 
chimeras (day 1) show positive CD31-FITC (green) staining of blood vessels in 
contrast to the IgG negative control. Sections were fixed in acetone and blocked in 
10% goat serum/PBST. Nuclei counterstained with To-pro-3-iodide (blue). 
Visualised by confocal microscopy.  
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Figure 8. Generation and analysis of radiation chimeras.  CLEC-2+/+ mice were 
reconstituted with approximately 2 x 106 CLEC-2+/+ or CLEC-2-/- foetal liver cells 
following irradiation induced depletion of the bone marrow. At various time points 
mice were sacrificed and blood and tissues taken for analysis.  
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Figure 9. Analysis of platelets in whole blood of radiation chimeras. Platelets 
counts and MPV’s were calculated from whole blood drawn from CLEC-2+/+ and 
CLEC-2-/- chimeras at 9, 21, 28 and 67 (CLEC-2-/- only) days post radiation. Blood 
was transferred directly into ACD and transferred into HEPES Tyrode buffer (see 
methods 2.313). Each time point marks an average of blood from two mice where 
vertical bars indicate the standard error of the mean.  
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Figure 10. FACS analysis of PRP at days 21 and 28 post radiation and 
reconstitution. PRP was stained for CD41 and CLEC-2 (CLEC-2+/+ chimeras, grey 
line, CLEC-2-/- chimeras, red line) along with IgG negative controls (CLEC-2+/+ 
chimeras, grey fill, CLEC-2-/- chimeras, black line). For 28 days, CLEC-2 data is 
presented as scatter plots where a change in shape for CLEC-2+/+ chimera PRP 
indicates platelet activation by the CLEC-2 antibody, not seen in PRP from mice 
reconstituted with CLEC-2-/- foetal liver cells. 
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Figure 11. Analysis of the intestinal phenotype in radiation chimeras. (A) CLEC-
2+/+ and CLEC-2-/- radiation chimeras at 21 and 28 days post radiation and 
reconstitution; arrow indicates initial signs of accumulation of blood in the intestinal 
mesentery in CLEC-2-/- chimeras at 28 days. (B) Intestines of CLEC-2fl/fl mice 
appear normal compared to a notably more bloody intestine in 
megakaryocyte/platelet specific CLEC-2fl/flPF4-Cre mice at 8 weeks. 
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Figure 12. Whole mount immunofluorescence staining of the intestinal mesentery. 
The intestinal mesentery of radiation chimeras at 9 days post radiation and 
reconstitution with CLEC-2+/+ and CLEC-2-/- platelets. Blood and lymphatic vessels 
stained with α-Endomucin (594-red) and α-Lyve-1 (FITC-green), respectively. 
Visualised by confocal microscopy.  
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Figure 13. Schematic diagram of the TUNEL assay technique for detection of 
apoptotic cells. Digoxigenin labelled dNTP’s (orange) are incorporated by TdT at 
the 3’OH of single and double strand breaks induced by radiation. Detection is 
through conjugation of an anti-digoxigenin-Rhodamine Ab.  
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Figure 14. Visualising rhodamine labelled apoptotic cells. TUNEL labelling of 
apoptotic cells (red) in CLEC-2+/+ E14.5 embryo cryosections and spleen and liver 
cryosections from CLEC-2+/+ radiation chimeras 9 days post radiation and 
reconstitution. Images on the bottom panel are of higher magnification to show co-
localisation of TUNEL labelled nuclei with To-pro-3-iodide (blue) stained nuclei. 
Visualised by confocal microscopy. 
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Figure 15. Quantifying the level of apoptosis occurring in spleen and liver sections 
of radiation chimeras. Three cryosections 20μm apart from CLEC-2+/+only for day 
1 and CLEC-2+/+ and CLEC-2-/- radiation chimera tissues at 9, 21 and 28 days 
post radiation and reconstitution were TUNEL labelled and 3 images per section 
analysed by widefield epiflourescent microscopy for the number of apoptotic (red) 
and DAPI (blue) stained nuclei in one frame of view at 40 X magnification. The 
percentage of apoptotic cells relative to DAPI stained nuclei in spleen (Ai) and liver 
(Aii) are plotted. Representative images of negative control (-TdT) and TUNEL 
labelled spleen (Bi) and liver (Bii) cryosections are shown. Scale bars represent 20 
μm. 
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  Primer Sequence (5’ to 3’) 
CLEC-2+/+ forward primer GAT GAG TCT GCT AGG GAT GC 
CLEC-2-/- forward primer CAG AGG AAG AAA ACT CAG AAG G 
CLEC-2 common reverse primer AGC CTG GAG TAA CAA GAT GG 
R41A forward primer AGG CGG GGG AAT TAG AAG TTG AAG 
R41A reverse primer AGT CTT TGG ACA CAG TCC TCA AGG G 
PF4-Cre forward primer TGC ACA GTC AGC AGG TT 
PF4-Cre reverse primer CCC ATA CAG CAC ACC TTT TG 
 
Table 1. Primer sequences for CLEC-2+/+, CLEC-2-/-, R41A and PF4-Cre 
genotyping. 
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Abstract 
 
Nitric oxide (NO) has long been accepted as a potent and powerful inhibitor of 
platelet function acting through soluble guanylyl cyclase (sGC) to elevate levels of 
cyclic guanosine 3’,5’-monophosphate (cGMP). In cells such as cardiac myocytes, 
cGMP levels are also influenced by natriuretic peptides (NP) which bind to a 
particulate GC (pGC). Despite a number of studies indicating binding sites for 
atrial NP (ANP) on platelets, their influence on platelet function is unclear. Here it 
is demonstrated that NO and ANP mediate concentration-dependant inhibition of 
platelet aggregation to thrombin which is not overcome by high concentrations of 
the protease. ANP also stimulated weak phosphorylation of vasodilator stimulated 
phosphoprotein (VASP) in contrast to the robust response to NO and which was 
highly variable between donors. Further, sildenafil, a selective PDE5 inhibitor, was 
shown to enhance NO but not ANP mediated platelet inhibition and VASP 
phosphorylation indicating soluble and particulate cGMP pools are 
compartmentalised in platelets. Together these findings indicate a role for ANP in 
inhibiting platelet function which is distinct from that of NO.  
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1.0 Introduction 
 
1.1. Background: Nitric oxide in regulating haemostasis 
 
NO is produced in endothelial cells and constitutively released into the circulation 
where it has many essential roles towards controlling vascular tone, blood 
pressure and in regulating haemostasis. NO also acts alongside prostacyclin 
(PGI2) to inhibit the activation of circulating platelets by elevating the levels of 
cAMP and cGMP, respectively[43]. Platelets express a vast array of surface 
receptors which are able to mediate rapid activation upon interacting with ligands 
such as thromboxane (TxA2), thrombin or ADP (Figure 1). Platelet activation is 
associated with shape change through re-organisation of the cytoskeleton, 
secretion of vasoactive molecules, up-regulation of surface receptors, adhesion to 
subendothelial matrix, and aggregation resulting in thrombus formation[1, 44]. Acute 
regulation of both inhibitory and activatory pathways is essential for controlling 
platelet function.  
. 
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Figure 1. Physiological factors influencing the inhibition and activation of platelets 
in the circulation. NO and PGI2 released from endothelial cells maintain platelets in 
a resting state. Exposure of the subendothelial matrix leads to binding of VWF to 
collagen and tethering of platelets via the GPIb-IX-V complex. The low affinity 
collagen receptor GPVI is then activated leading to firm adhesion to the blood 
vessel wall as a consequence of integrin activation (e.g. αIIbβ3). The release of 
feedback molecules, ADP and TXA2, promotes the recruitment of further platelets 
leading to aggregation and ultimately leading to thrombus formation. Adapted from 
Hoftbrand, Chapter 40[1]. 
 
1.2. Regulation of NO signalling pathways in platelets  
 
NO is the most important inhibitor of platelet function and so, understanding the 
mechanisms behind its regulation and signalling pathways may help in the 
development of new anti-thrombotic therapeutic strategies.  
NO stimulates sGC in platelets resulting in elevated levels of cGMP. cGMP acts 
synergistically to inhibit platelet function with cAMP, produced by adenylyl cyclase 
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(AC) which becomes activated upon interaction with a stimulatory G protein (Gαs) 
released on receptor interaction with PGI2 (Figure 2). The main targets of cGMP 
and cAMP are cGMP and cAMP-dependant protein kinases, also known as 
protein kinase G (PKG) and protein kinase A (PKA), respectively[45].  
The levels of cyclic nucleotides are strictly regulated to enable the platelet to 
effectively perform its physiological function. Although cyclic nucleotides are 
primarily regulated by their synthesis, a key point of regulation is through their 
degradation. This is achieved by a family of PDE’s which specifically hydrolyse 
cyclic nucleotides to produce biologically inactive 5’ nucleotides[43]. A range of 
PDE’s exist, each which vary in their subcellular location, mechanism of action 
and substrate specificity. In platelets, PDE 2, 3 and 5 are involved in regulating 
cAMP and cGMP levels and vice versa, through a complex web of interactions 
and feedback loops (Figure 2)[45]. For example, cGMP inhibits PDE3 to elevate 
levels of cAMP and enhance their inhibitory effect. The intricacy of the overlap 
between cAMP and cGMP signalling pathways is reflected their complex 
regulation by the PDE enzymes[46]. 
PDE inhibitors have been of great therapeutic interest as anti-platelet and anti-
thrombotic tools, allowing temporary sustained elevation of cyclic nucleotides, 
hence inhibition of platelet activation and vasorelaxation. The successful 
formulation and application of a specific PDE 5 inhibitor was developed by Pfizer, 
Sildenfil (ViagraTM) for treatment of erectile dysfunction[47].  
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1.3. Inhibitory pathways of PKG 
 
PKA and PKG target several agonist induced pathways in platelets, including 
cytoskeletal reorganisation, integrin activation and elevation of intracellular 
calcium levels[43]. An agonist induced increase in cytosolic calcium levels results 
from the activation of phospholipase C (PLC) which stimulates the production of 
the inositol-1,4,5-trisphosphate (IP3) receptor hence mediating the release of Ca
2+ 
and subsequent activation of Ca2+ regulated proteins[48]. PKG-1 but not PKA has 
been shown to mediate inhibition of platelet activation through phosphorylation of 
the IP3 receptor associated cGMP kinase substrate (IRAG), which is expressed in 
a macromolecular complex with PKG-1 and the IP3 receptor type 1. 
Phosphorylation of IRAG by PKG-1 inhibits IP3-induced Ca
2+ release and, 
importantly, targeted deletion of the IP3-binding region of IRAG prevents NO-
mediated inhibition of platelet activation, whereas the inhibitory effect of cAMP is 
retained[49]. PKG has also been shown to act on the sarcoplasmic reticulum 
ATPase (SERCA) to stimulate the re-filling of intracellular Ca2+ stores[48]. 
Although the molecular mechanisms are unclear, the down regulation of Ca2+ 
release by cyclic nucleotides is thought to occupy an additional role in inhibiting 
platelet secretion, thereby inhibiting the release of activatory molecules such as 
integrin αIIbβ3, P-selectin and CD40 ligand
[45]. PKG has additionally been shown to 
mediate phosphorylation of the TXA2 receptor which prevents receptor coupling to 
the GTP binding protein, Gq, thus inhibiting activation of PLC[50].  
Platelet proteins involved in cytoskeletal reorganisation that are thought to be 
potential substrates for PKA or PKG include heat shock protein 27 (Hsp27), 
myosin light chain kinase (MLCK), the GTPase, Rap1b and the vasodilator 
55 
 
stimulated phosphoprotein (VASP)[45]. The actin binding protein, VASP, is 
characterised as a prominent substrate for PKA/PKG in platelets where its 
phosphorylation correlates closely with inhibition of platelet aggregation[51]. VASP 
is a 50 kDa protein originally isolated in platelets but subsequently found to be 
expressed in a vast array of cells, including endothelial cells and T cells. VASP is 
an evolutionary conserved regulator of actin dynamics and is considered to have 
an array of physiological roles. In platelets, VASP is shown to localise to focal 
adhesion points where it is thought to occupy an anti-capping function to allow the 
extension of actin filaments[52, 53]. Three phosphorylation sites have been identified 
in VASP (serine 157, serine 239 and threonine 278). All three sites can be 
phosphorylated by PKA or PKG, although serine 157 and serine 239 are 
preferentially phosphorylated by PKA and PKG respectively[54]. VASP has been 
shown to influence the activation of integrin αIIbβ3 to disrupt fibrinogen binding 
hence inhibiting platelet aggregation[51].  The role of VASP as a negative regulator 
of platelet adhesion/aggregation is reflected in the enhanced exposure and 
activation of P selectin and αIIbβ3 in VASP deficient mice[55].  
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Figure 2. Production and regulation of cyclic nucleotides in platelets. The main 
inhibitor of platelet activation, NO, directly activates sGC leading to the generation 
of cGMP and activation of PKG. PKG interacts with many substrates to influence 
platelet function, including, IRAG, VASP and PDE3 which hydrolyses cAMP. A 
second inhibitor of platelet activation, PGI2 binds to a seven transmembrane 
protein coupled to Gs and thereby stimulates AC, increasing cAMP levels. 
Activatory stimuli such as thrombin and ADP also act through G proteins, 
releasing Gi and down regulating cAMP levels. cGMP is degraded by PDE5 and 
PDE2, negatively regulates PDE3 and positively regulates PDE5 and PDE2 to 
influence levels of cAMP which is degraded by PDE2 and PDE3. cGMP levels are 
also potentially influenced by natriuretic peptides (NP) binding to a pGC receptor. 
Adapted from Schwarz, 2001[45]. 
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1.4. Evidence for a pGC receptor on platelets 
 
In addition to sGC, cells such as cardiac myocytes have a cell membrane bound 
pGC receptor which is activated by the NP’s, atrial NP (ANP), brain NP (BNP) and 
C-type NP (CNP)[46]. NP receptors (NPR) A and B possess intrinsic GC activity 
within their cytosolic domains allowing localised production of cGMP (Figure 3). In 
contrast, NPR-C functions independently of guanylyl cyclase and regulates local 
NP concentrations through receptor mediated internalisation and degradation. 
ANP, BNP and CNP can act as ligands for each of the NP receptors with the NPR-
A having a higher affinity for ANP and BNP, and CNP having greater affinity for 
NPR-B. Similar to the role of NO, NP’s have vital roles in the maintaining 
cardioprotective responses to ischemia, vascular tone and cardiac contractility[56].  
It is currently unclear as to whether platelets contain a pGC receptor. Early work 
identified what was considered to be highly specific, yet reversible binding sites for 
ANP on platelets. However, ANP was shown to have no influence on cGMP levels 
and as such it was suggested that the receptor was not coupled to guanylyl 
cyclase[57]. This was supported by earlier work suggesting ANP had no significant 
physiological effect on platelet function[58]. This work was contradicted by Gear et 
al who proposed that ANP mediated an increase in cGMP levels in platelets which 
correlated with inhibition of platelet function; going on to suggest at least a 
proportion of ANP receptors on platelets are coupled to guanylyl cyclase[59]. It has 
also been suggested that ANP may contribute indirectly towards platelet inhibition 
by interfering with the inhibitory coupling of AC with agonist stimulation (e.g. 
ADP)[60]. More recently, platelets were confirmed to express NPR-C involved in the 
clearance and degradation of circulating natriuretic peptides but showed no effect 
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on intracellular cGMP levels in response to ANP[61]. More recent reviews refer to 
there being no pGC receptor on platelets but give no reference to support their 
conclusions[43, 45]. 
 
 
 
 
 
 
 
 
 
Figure 3. Natriuretic peptide receptor topology and ligand binding specificities. 
NPR-A and NPR-B have an extracellular ligand binding domain, single 
hydrophobic transmembrane domain, intracellular kinase, dimerization and 
guanylyl cyclase domains consisting of two active sites. NPR-C has only a 37 
amino acid intracellular domain, however the extracellular ligand binding domain 
has approximately 30% homology to NPR-A and NPR-B. Figure taken from Potter 
et al[56] 
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1.5. Compartmentation of cyclic nucleotide signalling pathways 
 
The idea that cyclic nucleotide signalling is compartmented in cells is becoming 
increasingly supported in the literature. The importance of this concept is reflected 
in the proposal that disorganisation in a cell, through the loss of compartmented 
signalling pathways reflects a disease state, for example, following heart failure[46].  
Studies on cardiac myocytes for example, postulate that cells are able to 
distinguish between single stimuli acting on a specific signalling cascade. In this 
way, the spatial and temporal effects of cyclic nucleotides appear to be mapped 
by the co-ordinated distribution of protein kinases (PKA/PKG), PDE’s, signalling 
proteins and their substrates[46, 62]. This concept can be extrapolated to platelets 
where it is postulated that signalling micro-domains, for example, at the platelet 
membrane or endoplasmic reticulum, may allow the effects of cGMP to be 
mediated without any significant change in global intracellular cGMP levels. PDE’s 
have been of particular interest of late and are proposed to form signalling micro-
domains within cells to direct a signal through specific signalling pathways[46]. This 
theory has been supported by Wilson et al who demonstrated the existence of a 
discrete microdomain in platelets, localised to Ca2+ channels. Within this 
microdomain, cGMP based control of Ca2+ release was regulated by the specific 
compartmentation of PDE5 with PKG[63]. Such local ‘undetectable’ changes in 
cGMP levels may allow tightened regulation of nearby Ca2+ channels and more 
transient changes to be effectively controlled. Adding to the complexity of NO 
signalling, sGC has been shown to translocate to the platelet membrane in 
response to agonist induced increases in intracellular Ca2+ where it becomes 
increasingly sensitised to NO, potentially to counteract the agonist response [64].  
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Membrane bound GC receptors form ideal localised domains for cyclic nucleotide 
signalling. It is postulated that pGC or sGC mediated elevation in cyclic 
nucleotides can have independent effects within a single cell such that, for 
example in cardiac myocytes, pGC activation works mainly to decrease 
intracellular Ca2+ levels while sGC signalling decreases Ca2+ sensitivity. If a similar 
situation exists in platelets, pGC could mediate signalling through alternative 
signalling pathways and mediate independent effects to sGC[62]. 
 
1.6. Aims of the study 
 
The aims of the project are several fold: 
i. Do platelets express a receptor for ANP 
ii. Do platelets express a pGC receptor 
iii. Does ANP mediate platelet inhibition and, if yes, is this mediated through 
pGC and how does the extent of inhibition compare to that of sGC 
iv. Can inhibitors of PDEs be used to distinguish between pGC and sGC 
signalling? 
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2.0. Methods 
 
2.1. Reagents 
 
Primary antibodies used were rabbit anti-human Phospho-VASP (Ser239) (Cell 
Signalling Technology) and goat anti human NPR-A (Santa Cruz Biotechnology) 
and rabbit anti human NPR-A (Fabbgenix) were gifts from Dr Rob Fowkes, Royal 
Veterinary College, University of London. Secondary antibodies used were ECL™ 
donkey anti-rabbit IgG horse raddish peroxidase (HRP) (GE Healthcare) and 
donkey anti-goat IgG HRP (Santa Cruz Biotechnology). Additional materials used 
include Pierce® ECL western blotting substrate (Thermo Scientific), concentrated 
citrate solution, atrial natriuretic peptide (ANP), S-nitrosoglutathione (GSNO), 
isobutyl-1-methylxanthine (IBMX), diethylamine NONOate (DEANO) and thrombin 
(Sigma Aldrich), thrombin receptor activator peptide 6 (TRAP-6) (Altabioscience) 
and sildenafil citrate was a gift from Pfizer. 
 
2.2. Preparation of human platelets 
 
Whole blood was drawn from healthy volunteers into sodium citrate (1/10 vol) and 
further anti coagulated with acid citrate dextrose (ACD) (1/10 vol) to give a final 
citrate concentration of 3.8%. Platelets were obtained by centrifugation using PGI2 
(final concentration of 10 µg) to prevent activation during isolation. Washed 
platelets were re-suspended in modified HEPES Tyrode buffer (134 mM NaCl, 2.9 
mM KCl,12 mM NaHCO3, 0.34 mM NaH2PO4, 1 mM MgCl2, 5.5 mM glucose, 1 
62 
 
mM MgCl2, 20 mM HEPES, and 5 mM glucose, pH 7.3) to a concentration of 2 X 
108 platelets/ml for aggregation studies or 5 X 108 platelets/ml for western blotting.  
 
2.3. Aggregation studies 
 
Washed platelets (490 µl at 2 x 108 platelets/ml) were incubated at 37°C for 5 min. 
NO donors (GSNO or DEANO), ANP or phosphate buffered saline (PBS) were 
added and the sample was incubated at 37°C for a further 60 sec with stirring 
before stimulation with thrombin or TRAP-6. Where applicable, the PDE inhibitors, 
sildenafil (PDE5 inhibitor), IBMX (PDE2, PDE3 and PDE5 inhibitor) or control 
vehicle, 0.1 % dimethyl sulfoxide (DMSO), were added one minute prior to 
addition of NO donor or ANP. Aggregation was monitored by light transmission 
using Born lumi-aggregometer. Aggregation data is plotted as percent aggregation 
or percent inhibition of aggregation where 100 % represents maximal light 
transmission or maximal inhibition of light transmission, respectively. Points are 
mean values with standard error of the mean (s.e.m) shown by vertical bars.  
 
2.4. Preparation of whole cell lysates  
 
Washed platelets (290 µl at 5 x 108 platelets/ml) were left resting or stimulated as 
described (2.3) and samples lysed at different time points with 5 x sample buffer 
(10% sodium dodecyl sulphate (SDS), 25% 2-mercaptoethanol,  50% glycerol, 
25%  0.5 M Tris HCl, pH 6.8, Brilliant Blue R, trance). Samples were immediately 
placed on ice before boiling at 100 ºC for 5 min and then stored at -20 ºC. Prior to 
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use, samples were defrosted thoroughly on ice and cellular debris pelleted by 
centrifugation (14, 000 x g for 3 min) at 4 ºC. 
 
2.5. Western Blotting 
 
Sample proteins were separated on a 12 % (Phospho VASP (Ser239)) or 8 % (α-
NPR-A) SDS polyacrylamide gel in a Biorad tank with 1 X running buffer (0.025M 
Tris, 0.192 M Glycine and 0.1 % SDS) at 50 V through the stacking gel (stacking 
buffer; 0.5 M Tris-HCL, pH 6.8) and increased to 90 V through the resolving gel 
(resolving buffer; 3.0 M Tris-HCL, pH 8.8). Proteins were transferred to a PVDF 
membrane through a wet transfer method where the PVDF membrane and gel are 
sandwiched within a cassette in a Boriad tank. The central cassette is filled with 
transfer buffer (24 mM Tris, 191 mM glycine in 1:4 methanol:water) and the outer 
tank with water and transferred at 30 V for 90 minutes at 4°C. PVDF membranes 
were incubated in blocking solution (5 % bovine serum albumin (BSA), 0.1 % 
sodium azide in Tris buffered saline containing Tween 20 (TBS-T); 20 mM Tris 
base, 137 mM NaCl in distilled water, adjusted to pH 7.6 and 2 ml Tween 20 
added) for 1 hour at room temperature or overnight at 4 °C. PVDF membranes 
were then incubated in primary antibody, diluted 1:1000 in blocking solution, for 1 
hour at room temperature or at 4 °C overnight followed by 3 x 15 min washes in 
TBS-T. PVDF membranes were then incubated in secondary antibody, diluted 
1:10000 in TBS-T, for 1 hour at room temperature or overnight at 4 °C followed by 
3 x 15 min washes in TBS-T. Excess TBS-T was removed from membranes 
before immersion in ECL for 60 sec, membranes were wrapped in cling-film and 
placed protein side up into a film cassette. Hyperfilm was placed on top of the 
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blots within the cassette in the dark and exposed for the appropriate time before 
processing (Compact X5, Xograph imaging systems).     
 
2.5.1. Stripping membranes                  
      
PVDF membranes were rinsed in methanol before stripping in stripping buffer 
(TBS containing 2 % Tween 20 and 2 % SDS) containing 0.1 % 2-
mercaptoethanol for 20 min at 80 °C. Membranes were further incubated in 
stripping buffer alone for 20 min at 80 °C before washing in TBS-T. Membranes 
were blocked in 5 % milk powder in PBS containing 0.1 % Tween 20 (PBS-T) for 1 
hour at room temperature. 0.05 % sodium azide was added to blocking solution 
and membranes incubated for a further hour at room temperature. Membranes 
were washed in TBS-T before incubating in primary antibody (α-NPR-A, 
Fabgennix) diluted in 5 % milk powder/PBST overnight at 4 °C. Membranes were 
washed 3 x 15 min in TBS-T before incubating in secondary antibody (donkey 
anti-rabbit HRP diluted 1:10000 in TBS-T) for 1 hour at room temperature. 
Membranes were processed as described previously in methods (2.5).       
 
 
 
 
 
65 
 
3.0. Results 
 
3.1. Investigating the expression of NPR-A on the platelet membrane 
  
The initial aim of the study was to identify whether platelets express a receptor for 
ANP and whether this receptor is coupled to GC. The pGC receptor, NPR-A, binds 
with greatest affinity to ligand ANP and has been shown to be highly expressed in 
kidney, adrenal, adipose, aortic and lung tissues[56]. NPR-A can be differentially 
glycosylated resulting in apparent molecular masses of 122 kDa or 130 kDa[65]. A 
band of this approximate size can be seen in a cardiac myocyte cell lysate 
western blotted for NPR-A (Figure 4). A series of bands running across the 
membrane, just below this are apparent in platelet lysates which may represent a 
less glycosylated form of the receptor (Figure 4). Different concentrations of ANP 
or its replacement with GSNO were included to observe any influence on receptor 
expression on the platelet. However, the high number of non specific binding sites 
of the NPR-A antibody make it difficult to firmly conclude the presence of the 
receptor on platelets. A second antibody (NPR-A, Fabgenix) to the receptor was 
applied to the membranes using an alternative protocol in attempt to enhance 
detection and reduce non specific binding, however, no bands of the expected 
molecular mass were observed (data not shown). 
Given the uncertainty as to the expression of a receptor for ANP on platelets, 
alternative strategies were employed to investigate whether the peptide has any 
inhibitory effects on platelet function. Such analysis was to be performed 
alongside investigating the inhibitory effects of NO on platelets to allow relative 
comparisons. 
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3.2. Comparing the inhibitory effects of NO donors and ANP on platelet 
aggregation   
 
Each of the NO donors within the vast array that are commercially available have 
varied effects across different tissues and in response to different agonists[66]. For 
this reason it was decided to investigate the inhibitory effects of two different NO 
donors, GSNO and DEANO in combination with two platelet agonists, thrombin 
and TRAP-6. Thrombin was selected on the basis of it being among the most 
powerful platelet agonists, mediating cleavage of the protease-activated receptors 
(PAR-1 and PAR-4) releasing a tethered ligand to bind and activate the receptor. 
TRAP-6, which will be referred to as PAR-1, is a synthetic peptide mimicking the 
binding sequence of the tethered ligand (serine-phenylalanine-leucine-leucine-
arginine-asparagine)[1].  
Thrombin induced maximal platelet aggregation at 0.03 u/ml (Figure 5A). Hence, 
this concentration of thrombin was taken as the threshold concentration for use in 
further experiments. Following pre-incubation with varying concentrations DEANO 
or GSNO, the extent of inhibition of platelet aggregation was determined. Platelet 
aggregation was only mildly inhibited at 0.1 μM and 1 μM GSNO with full inhibition 
of platelet aggregation being observed at 10 μM GSNO (Figure 5B and Ci). A ten-
fold higher concentration of DEANO (100 μM) was required to consistently achieve 
maximal platelet inhibition (Figure 7A and 7Bi).  When increasing the 
concentration of thrombin to 0.1 u/ml, the inhibitory effect of 10 μM GSNO or 100 
μM DEANO was overcome and the ability of platelets to form aggregates restored 
(Figure 5Cii and 7Bii).  
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PAR-1 stimulated near maximal platelet aggregation at the threshold 
concentration of 10 μM and as such this concentration was taken for use in further 
experiments (Figure 6A). Both GSNO and DEANO mediated inhibition of platelet 
aggregation following stimulation with PAR-1 in a dose dependant manner, with a 
ten-fold lower concentration of DEANO mediating greater inhibition than was 
observed when stimulating with thrombin (Figure 6B, 6Ci and 7A, 7Ci). 
Reminiscent of the responses observed when stimulating with thrombin, when 
treating platelets with inhibitory concentrations of GSNO (10 μM) or DEANO (100 
µΜ) aggregation could be restored when increasing concentrations of PAR-1 to 30 
µM and 100 µM (Figure 6Cii and 7Cii). 
Importantly, ANP was also observed to mediate concentration-dependant 
inhibition of platelet aggregation when stimulating with thrombin or PAR-1 (Figures 
8A, Bi and Ci). Additionally, in contrast to what was observed with NO donors, 
platelet aggregation could not be restored when increasing thrombin or PAR-1 
concentrations to 0.1 u/ml or 30 µM, respectively, following pre-incubation with 10 
μM ANP (Figures 8Bii and Cii). 
Higher variability was observed at the intermediate concentrations of NO donors 
or ANP potentially due to higher donor variability. GSNO was selected as a 
preferential NO donor for use in further experiments solely due to the lower 
concentration required to consistently mediate full inhibition of platelet 
aggregation. 
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3.3. Comparing VASP phosphorylation in platelets treated with GSNO or 
ANP 
 
As discussed, VASP is phosphorylated by PKA and PKG preferentially at serine 
157 and serine 239, respectively. Phosphorylation at serine 157 results in a 
mobility shift on an SDS-PAGE gel from 46 kDa to approximately 50 kDa, hence 
the two bands observed when immunoblotting with antibody phospho-VASP (Ser 
239) (Figure 9). Control platelets, or platelets stimulated with thrombin gave no 
detectable levels of phospho-VASP (Ser239), with PAR-1 peptide inducing only 
weak phosphorylation at 1 and 3 minutes (Figure 9). Since the inhibitory effects or 
propensity to mediate VASP phosphorylation by GSNO were highly similar 
between thrombin or PAR-1 stimulated platelets, thrombin was selected for future 
experiments involving NO donors based on its greater physiological relevance. 
When stimulating platelets with thrombin, a marginal increase in VASP 
phosphorylation was apparent (Figure 9 and 10A). Additionally, phospho-VASP 
(Ser239) levels appeared to peak at 1 min post stimulation with agonist (Figure 9 
and 10A). Compared to the dose dependant increase in inhibitory effect of GSNO 
on platelet aggregation (Figure 5B), the intensity of bands indicative of phospho-
VASP (Ser239) were seen to increase up to 1 µM  GSNO where phosphorylation 
appeared to become maximal (Figure 10A). 
Similar results were obtained from the same donor when pre-treating platelets with 
ANP. In the absence of thrombin, ANP mediated a concentration dependant 
increase in VASP phosphorylation, albeit bands appeared to be of significantly 
lower intensity to those derived from GSNO treated platelets. No difference in 
phospho-VASP (Ser239) levels were visible between 1 and 3 min post stimulation 
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with thrombin which appeared to become maximal above 0.1 µM ANP (Figure 
10B). 
The variable effects NO has within platelets derived from different donors is shown 
by the enhanced response to GSNO observed in figure 10C where maximal 
intensity bands for phospho-VASP (Ser239) are observed at a tenfold lower 
concentration of GSNO (0.1 µM) to what was seen in figure 10A. In this instance, 
ANP was shown to cause minimal or no VASP phosphorylation in thrombin 
stimulated platelets and even appeared to dampen down GSNO mediated VASP 
phosphorylation (Figure 10C).  
 
3.4. Effects of the PDE5 inhibitor, sildenafil, on platelet aggregation and 
VASP phosphorylation 
 
PDE5 is a key regulator of cGMP levels in platelets. Inhibition of PDE5 by 
pharmacological agents such as sildenafil, have been shown to effectively 
enhance the effects of cGMP. Here, platelet aggregation in response to treatment 
with sildenafil and in combination with GSNO or ANP was assessed in attempt to 
further investigate a possible signalling pathway for ANP and additionally establish 
any evidence for compartmentation of cyclic nucleotide signalling in platelets. 
No effect on platelet aggregation was observed in platelets pre-treated with 
increasing concentrations of sildenafil (0.01 μM to 10 μM) prior to stimulation with 
thrombin (Figure 11A). When sildenafil was applied in combination with a fixed, 
sub maximally inhibitory concentration of GSNO (0.1 μM), platelet aggregation 
was largely inhibited an effect that was enhanced with increasing concentrations 
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of sildenafil (Figure 11A and Bi). In contrast, sildenafil did not enhance inhibition of 
platelet aggregation when in combination with a submaximal inhibitory 
concentration of ANP (0.1 μM) (Figure 11A and Bii). The slightly attenuated 
inhibition of platelet aggregation with 0.1 μM ANP compared to that seen in figure 
8A may result from the marginal increase in thrombin concentration (0.05 u/ml 
compared to 0.03 u/ml used previously) used to stimulate the platelets. The 
increase in thrombin concentration was used to give reproducible platelet 
aggregation in a given donor platelet sample which was slightly less responsive to 
thrombin and was used thereafter for consistency. 
Interestingly, non-treated platelets stimulated with thrombin gave rise to a 
significant level of phospho-VASP (Ser239) (Figure 11C). The extent of 
phosphorylation in thrombin stimulated platelets pre-treated with sildenafil 
increased minimally with rising concentrations of sildenafil. However, the inherent 
contribution of thrombin stimulated VASP phosphorylation is likely to have had a 
major influence towards the observed band intensities. Sildenafil enhanced the 
levels of phospho-VASP (Ser239) compared to platelets treated with sildenafil or 
GSNO alone, supporting their combined inhibitory effect on platelet aggregation. 
As observed previously (Figure 10C), no phospho-VASP (Ser239) was seen in 
platelets treated with 0.1 μM ANP alone. When applied in combination with 
sildenafil, no enhancement in phospho-VASP (Ser239) was apparent relative to 
platelets treated with sildenafil alone. These data support the negligible effect of 
sildenafil in combination with the sub maximally inhibitory concentration of ANP 
(0.1 μM) on platelet aggregation. ANP appeared to suppress VASP (Ser239) 
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phosphorylation in thrombin stimulated platelets treated with 10 μM sildenafil but 
had no visible effect when combined further with GSNO (Figure 11C). 
 
3.5. Effects of the non-specific PDE inhibitor, IBMX, on VASP 
phosphorylation 
 
Since the effects of PDE5 inhibitor sildenafil appeared minimal towards enhancing 
the effects of ANP, it would suggest that if ANP is mediating platelet inhibition 
through cGMP/cAMP, an alternative PDE would be involved in regulating its 
actions. The non specific PDE inhibitor, IBMX, inhibits the activity of PDE2, PDE3 
and PDE5, the three known platelet PDE’s and hence was employed to further 
tease out a potential role for ANP in cyclic nucleotide signalling.  IBMX has been 
used previously in platelets at concentrations ranging from 10 μM to 1000 μM[67, 
68]. Here 150 μM was selected for use based on studies in cardiac myocytes 
where this concentration was sufficient to enhance ANP-induced inhibitory 
responses[69]. 
Although GSNO mediated VASP (Ser239) phosphorylation was significantly 
enhanced in combination with IBMX, little effect was observed in combination with 
ANP, potentially due to the observed negligible basal contribution of ANP towards 
phospho-VASP (Ser239) levels (Figure 12).  
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4.0. Discussion 
 
4.1. Evidence for compartmentation of NO and ANP signalling in platelets 
 
Bands running at the approximate size of an unglycosylated form of NPR-A (119 
kDa) were visible in platelet lysates. However, the high levels of background and 
low specificity of the NPR-A antibody meant it was not possible to confirm the 
presence of a pGC receptor on platelets in this study. Alternative strategies were 
employed to investigate any inhibitory effect of ANP on platelet function. 
Characterising NO-induced platelet inhibition was a key control for relatively 
analysing any ANP-induced inhibitory effects. 
ANP was shown to mediate irreversible inhibition of platelet aggregation at the 
maximal inhibitory concentration of 10 µM, leaving platelets unable to respond and 
aggregate to increasing concentrations of agonist. Conversely, although NO 
donors, GSNO and DEANO mediated similar dose dependant inhibition of platelet 
aggregation, aggregation could be effectively restored with increasing 
concentrations of agonist showing platelets remained responsive. This gives the 
first evidence in this study that NO and ANP signalling are compartmented in 
platelets allowing independent inhibitory effects on platelet function.  
 
4.2. ANP mediates inhibition through VASP independent pathways 
 
ANP was shown predominantly not to mediate VASP phosphorylation and where 
observed, phosphorylation was weak, suggesting VASP is not central to the 
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signalling pathway employed by ANP to mediate the observed inhibition of platelet 
aggregation. It has already been suggested that ANP may mediate platelet 
inhibition through an alternative mechanism to NO, a theory that is supported by 
the much lower levels of VASP (Ser239) phosphorylation comparative to GSNO 
treated platelets from the same donor. Possible mechanisms that are employed by 
NP’s in other physiological systems, such as in smooth muscle relaxation, include 
the stimulation of Ca2+ channels at the membrane (e.g. Ca2+/ATPase) or in 
intracellular compartments (e.g. SERCA) combined with inhibition of Ca2+ 
releasing receptors such as IP3
[56].  Thereby it be postulated that signalling by 
ANP could be compartmented to the plasma membrane or intracellular 
compartments to cause localised inhibitory effects. This is supported by work 
demonstrating the redistribution of PKG to the plasma membrane upon stimulation 
with ANP, where PKG directly interacts with NPR-A[70]. Additionally, in vascular 
smooth muscle cells, significantly lower levels of ANP were shown to activate 
cyclic nucleotide gated channels more rapidly than NO donors indicating ANP may 
perform unique actions to NO donors and compartmentation of ANP signalling 
may strategically enhance its inhibitory effects[69]. 
Where ANP appeared to cause a reduction in VASP (Ser239) phosphorylation in 
GSNO treated platelets (Figure10C), it can be speculated that ANP signalling 
through VASP independent pathways reduces the intensity of NO signalling as 
PKG becomes localised to discrete compartments. The irreversible inhibition of 
platelet aggregation previously observed at 10 µM ANP links the potential 
enhanced potency of compartmentalised cyclic nucleotide signalling to enable 
constitutive inhibition. Additionally, a phenomenon that is becoming increasingly 
documented and could account for the much greater suppression of VASP 
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phosphorylation observed at 10 μM ANP is the desensitization of GC receptors 
resulting from continued exposure to NP’s. Desensitisation is caused by 
constitutive dephosphorylation of cytoplasmic residues in the kinase homology 
domain of NPR-A (Figure 3) rendering it inactive[71].  This analogy does not 
however link in with the irreversible inhibition of platelet aggregation observed at 
10 μM ANP which would suggest receptors are constitutively active. 
As mentioned, GSNO mediated high levels of VASP (Ser239) phosphorylation 
supporting the role of VASP in NO mediated inhibition of platelet aggregation. The 
slight increase in VASP phosphorylation in platelets treated with GSNO and 
further stimulated with thrombin, may reflect the ability of NO to respond rapidly to 
counteract platelet activation and lends itself to the idea that sGC is 
compartmented with its substrate VASP within the platelet to enable rapid 
propagation of signals.  
Phosphorylation of VASP did not correlate directly with the GSNO dose 
dependant inhibition of aggregation such that above a threshold concentration, 
e.g. 0.1 µM GSNO (Figure 10C), phosphorylation appeared equivalent and 
sustained. This suggests that inhibitory substrates other than VASP contribute to 
the elevated inhibitory effect of GSNO at higher concentrations. For example, in 
rat platelets, the relative inhibitory effects of sGC vary between tissues and 
inhibition is thought to be largely through stimulation of calcium re-uptake into 
intracellular stores through activation of proteins such as sarco-endoplasmic 
reticulum calcium-ATPase SERCA[66]. 
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4.3. Evidence for thrombin stimulated PKG independent phosphorylation of 
VASP 
 
Interestingly, in some cases western blot analysis of non treated platelets 
stimulated with thrombin gave rise to significant levels of phospho VASP (Ser239). 
Phosphorylaion of VASP at Ser 157 has been observed previously in platelets 
stimulated with thrombin (Naseem, unpublished observations). It has been 
suggested that phosphorylation of VASP (Ser157) in response to thrombin may be 
derived from protein kinase C (PKC) and Rho kinase dependant pathways[54]. 
Here, the majority of thrombin induced VASP (Ser239) phosphorylation is seen at 
46 kDa indicating minimal phosphorylation of Ser 157. One explanation for this 
comes from studies in human embryonic kidney (HEK-293) cells where PKC was 
shown to mediate phosphorylation and activation of PKG, hence allowing 
phosphorylaion of VASP (Ser 239)[72]. 
 
4.4. ANP mediated platelet inhibition is not regulated by PDE5 
 
Comparative to what has been observed previously in platelets, sildenafil alone 
had no effect on platelet aggregation but enhanced the inhibitory effects of GSNO 
by sustaining the levels of cGMP[73]. This is also reflected by the increase in VASP 
(Ser239) phosphorylation in platelets treated with both sildenafil and GSNO.  
Increasing cGMP levels have been shown to synergise with elevated cAMP levels 
through the cGMP mediated inhibition of PDE3[74]. Since it is suggested that PDE3 
is responsible for around 80 % of cAMP hydrolysis required to prevent platelet 
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aggregation, this is likely to be a key contributor to the observed inhibitory 
effect[75].  
In contrast, sildenafil was shown to have no effect on platelet inhibition by ANP, 
with phospho-VASP (Ser239) band intensities of the representative samples 
resembling those of platelets treated with sildenafil alone.  Such findings are in 
agreement studies in cardiac myocytes where the specific distribution of different 
PDE’s have been found to play key roles in controlling pGC and sGC cGMP pools. 
It was observed that PDE5 is critically involved in controlling the soluble pool of 
cGMP yet dispensable for the particulate pool which it is said to be under the 
exclusive control of PDE2[62]. Conversely, PDE5 was shown to be a key regulator 
of cGMP-mediated vasodilation of blood vessels by ANP in the pulmonary but not 
systemic circulation, highlighting the critical complexity of regulation, highly 
determinant of the physiological environment[76]. The severely suppressed 
phosphorylation of VASP (Ser239) in platelets treated with 0.1 µM ANP and 10 µM 
sildenafil (Figure 11C), potentially results from allosteric activation of PDE2 
resulting from a high concentration of sildenafil[75]. Since it has been suggested 
the pGC pool may be strictly regulated by PDE2, the drastic decrease in VASP 
(Ser239) phosphorylation correlates with a diminished particulate cGMP pool. 
The apparent negligible contribution of PDE5 towards platelet inhibition and VASP 
phosphorylation by ANP suggests that if ANP signalling is directed through cGMP 
pools, they are not regulated by PDE5. The non-specific PDE inhibitor, IBMX was 
employed in attempt to further investigate any regulatory role of PDE’s in ANP 
signalling.  
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IBMX significantly enhanced GSNO induced VASP (Ser239) phosphorylation 
further highlighting the importance of PDE’s in regulating the soluble cGMP pool. 
Where ANP alone caused no visible phosphorylation of VASP, it is not surprising 
that in platelets treated with both ANP and IBMX, levels of VASP phosphorylation 
were representative of those treated with IBMX alone. Further work is required to 
assess the contribution of PDE’s in regulating platelet inhibition through ANP. In 
cardiac myocytes it has been shown that PDE’s have minimal influence in 
regulating the pGC cGMP pool and instead are under the strict regulation of PKG 
which positively regulates the pGC receptor[77]. 
It is also possible that ANP binds to NPR-C, a receptor shown previously to be 
present on platelets which has high affinity for ANP and has been seen inhibit AC 
activity[61, 78]. This correlates with the low levels of ANP induced VASP 
phosphorylation at serine 157 (50 kDa bands), a site which is predominantly 
phosphorylated by cAMP. The preferential phosphorylation of VASP at Ser239 by 
ANP have been noted in previous studies and suggest ANP signals through a 
PKG dependant mechanism[79]. The mechanisms by which NPR-C may influence 
cGMP pools are however unknown.  
It is additionally entirely possible that given the inconsistent and minimal 
phosphorylation of VASP, ANP inhibits platelets by a cGMP independent 
mechanism. For example, cGMP analogs have been shown to cause rapid 
inhibition of thrombin, TXA2 or vWF induced platelet activation through an 
unknown PKG independent mechanism[80]. 
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5.0. Conclusion 
 
Through functional analysis it is demonstrated that ANP can bind to platelets and 
mediate inhibition of platelet function. ANP and GSNO were shown to have 
differential effects on VASP, hence, it is proposed that if ANP signalling is cGMP 
dependant, soluble and particulate cGMP pools are compartmented, regulate 
different signalling pathways and are themselves, differentially regulated. For 
example ANP may mediate inhibition by controlling the activity of Ca2+ channels at 
the platelet membrane or endoplasmic reticulum regulated independently of 
PDE5. The irreversible inhibition of platelet aggregation and suppression of VASP 
phosphorylation by 10 μM ANP is an intriguing result that despite speculation 
remains unexplained yet supports the idea of compartmentation of ANP and NO 
signalling. Much more work over a vast range of donors is required to unravel a 
mechanism by which ANP mediates inhibition of platelets and the mode of its 
regulation. 
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6.0. Future directions 
 
Determining the presence of a pGC receptor on platelets remains a key aim for 
future work. Protocol development strategies to enhance the specificity for 
detection of NPR-A are required. Additionally it is of interest to confirm the 
presence of NPR-C and quantitate the levels of the receptor on the membrane. 
Unravelling the mechanism by which ANP mediates inhibition of platelet 
aggregation is a key future aim. Completing studies using IBMX as well as 
independent studies using an inhibitor of PDE2, for example, erythro-9-(2-hydroxy-
3-nonyl)adenine or inhibitors of PKG, for example, KT5823, are crucial towards 
determining the involvement of cGMP and its mode of regulation[62, 77].  
Applying an inhibitor of sGC, for example, ODQ (1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one) and measuring the intracellular levels of cGMP using detection 
methods such as the cGMP enzyme immunoassay (EIA) kit (Cayman Chemicals) 
would enable the individual contribution of ANP to be quantified (d'Emmanuele di 
Villa Bianca, in press).  
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7.0. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4. Investigating the expression of NPR-A in platelets. Positive (+ve) control 
of whole mount heart, 10% homogenate. For the remaining lanes, washed 
platelets (5 x 108/mL) were incubated with ANP or GSNO and stimulated with 
thrombin (S) or left unstimulated (U). Samples were lysed with 5 X sample buffer, 
proteins separated by SDS-PAGE and western blotted for α-NPR-A. Molecular 
weight markers indicated to the right. Block arrow to the left of the gel indicates a 
band at approximately 130 kDa in the +ve control lane. (n=2). 
 
 
 
 
 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. GSNO mediates concentration dependant inhibition of thrombin 
stimulated platelet aggregation. Mean concentration response curves for (A) 
platelets aggregated with increasing concentrations of thrombin, expressed as 
percentage of maximal aggregation (n=4), (B) platelets pre-treated with GSNO for 
1 min and aggregated sub-maximally with thrombin (0.03 u/ml), expressed as 
percentage of inhibition of aggregation obtained in the absence of GSNO (n=3). 
(Ci and Cii) Representative aggregation traces (Ci) GSNO concentration 
response, (Cii) increasing concentrations of thrombin with a fixed concentration of 
GSNO (10 µM). Arrow heads indicate addition of NO donor or agonist. 
Experiments were conducted in aggregometer cuvettes with stirring at 37°C.  
   (Ci) 
(A) (B) 
(Cii) 
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Figure 6. GSNO mediates concentration dependant inhibition of PAR-1 stimulated 
platelet aggregation. Mean concentration response curves for (A) platelets 
aggregated with increasing concentrations of PAR-1, expressed as percentage of 
maximal aggregation (n=3), (B) GSNO treated platelets aggregated sub-maximally 
with PAR-1 (10 µM), expressed as percentage of inhibition of aggregation 
obtained in the absence of GSNO (n=3). (Ci and Cii) Representative aggregation 
traces; (Ci) GSNO concentration response, (Cii) increasing concentrations of 
PAR-1 with a fixed concentration of GSNO (10 µM). Arrow heads indicate addition 
of NO donor or agonist. Experiments were conducted in aggregometer cuvettes 
with stirring at 37°C.  
(A) (B) 
(Ci) (Cii) 
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Figure 7. DEANO mediates concentration dependant inhibition of thrombin or 
PAR-1 stimulated platelet aggregation. (A) Mean concentration response curves to 
DEANO treated platelets aggregated sub-maximally with thrombin (0.03 u/ml) or 
PAR-1 (10 µM), expressed as percentage of inhibition of aggregation obtained in 
the absence of DEANO (n=3). (B and C) Representative aggregation traces; (Bi or 
Ci) DEANO concentration response with agonists thrombin (0.03 u/ml) or PAR-1 
(10 µM), (Bii or Cii) increasing concentrations of thrombin or PAR-1 with a fixed 
concentration of DEANO (100 µM). Arrow heads indicate addition of NO donor or 
agonist. Experiments were conducted in aggregometer cuvettes with stirring at 
37°C.  
 
 
 
 
 
 
.    
 
 
 
 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Bi) 
(A) 
Aggregating agent Thrombin 
 
Aggregating agent PAR-1 
 
(Bii) 
(Ci) (Cii) 
86 
 
Figure 8. ANP mediates concentration dependant inhibition of aggregation in 
thrombin and PAR-1 stimulated platelets. (A) Mean concentration response curves 
to ANP treated platelets aggregated sub-maximally with thrombin (0.03 u/ml) or 
PAR-1 (10 µM), expressed as percentage of inhibition of aggregation obtained in 
the absence of ANP (n=3 except for points 0.01 µM and 0.1 µM ANP when 
aggregating with PAR-1; n=1). (B and C) Representative aggregation traces; (Bi or 
Ci) ANP concentration response with agonists thrombin (0.03 u/ml) or PAR-1 (10 
µM), (Bii or Cii) increasing concentration of thrombin or PAR-1 with a fixed 
concentration of ANP (10 µM). Arrow heads indicate addition of ANP donor or 
agonist. Experiments were conducted in aggregometer cuvettes with stirring at 
37°C.  
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Figure 9. GSNO mediated VASP phosphorylation in thrombin and PAR-1 
stimulated platelets. Washed platelets (5 x 108/ml) were incubated with GSNO or 
PBS and stimulated with thrombin, PAR-1 or left unstimulated for control or 
platelets treated with GSNO alone. Samples were lysed with 5 X sample buffer, 
proteins separated by SDS-PAGE and western blotted for phospho-VASP 
(Ser239). Molecular weight markers indicated to the right (n=1). 
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Figure 10. Concentration and time dependent phosphorylation of VASP (Ser239) 
by GSNO and ANP. Washed platelets (5 x 108/ml) were incubated with different 
concentrations of GSNO (A & C), ANP (B & C), ANP and GSNO together (C) or 
PBS one minute prior to stimulation with thrombin (0.03 u/ml) or left unstimulated 
for control platelets. Samples were lysed at different time points with 5 X sample 
buffer, proteins separated by SDS-PAGE and western blotted for phospho-VASP 
(Ser239). Washed platelets prepared for C are from a different donor to A and B, 
which are from the same donor. Molecular weight markers indicated to the right. 
(n=1)    
(A) 
(B) 
(C) 
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Figure 11. Sildenafil enhances platelet inhibition by GSNO but not ANP (A) Mean 
concentration response plots to platelets treated with sildenafil alone or 
additionally with GSNO (0.1 µM) or ANP (0.1 µM) and aggregated sub-maximally 
with thrombin (0.05 u/ml) (n=3). (Bi and Bii) Representative aggregation traces for 
GSNO (Bi) and ANP (Bii) treated platelets. (C) Washed platelets (5 x 108/ml) were 
treated where indicated with sildenafil, GSNO or ANP prior to stimulation with 
thrombin (0.05 u/ml) or left unstimulated for control platelets. Samples were lysed 
at 1 min post stimulation with 5 X sample buffer, proteins separated by SDS-
PAGE and western blotted for phospho-VASP (Ser239) (n=1). Experiments were 
conducted in aggregometer cuvettes with stirring at 37°C. Molecular weight 
markers indicated to the right. 
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Figure 12. IBMX enhances VASP phosphorylation in GSNO but not ANP treated 
platelets. Washed platelets (5 x 108/ml) were treated where indicated with IBMX, 
GSNO and ANP prior to stimulation with thrombin (0.05 u/ml) or left unstimulated 
for control platelets. Samples were lysed at 1 min post stimulation with 5 X sample 
buffer, proteins separated by SDS-PAGE and western blotted for phospho-VASP 
(Ser239). Experiments were conducted in aggregometer curvettes with stirring at 
37°C. Molecular weight markers indicated to the right.   
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